



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵: C12N 15/06, C12P 21/08, G01N 33/577, 33/574, 33/564, 33/68, C07K 15/00, A61K 39/395, 49/02	A1	(11) International Publication Number: WO 94/12631 (43) International Publication Date: 9 June 1994 (09.06.94)
(21) International Application Number: PCT/GB93/02394 (22) International Filing Date: 22 November 1993 (22.11.93) (30) Priority Data: 9224386.4 20 November 1992 (20.11.92) GB 9226165.0 16 December 1992 (16.12.92) GB PCT/GB93/01520 20 July 1993 (20.07.93) WO (34) Countries for which the regional or international application was filed: AT et al. (71) Applicant (for all designated States except US): ISIS INNOVATION LIMITED [GB/GB]; 2 South Parks Road, Oxford OX1 3UB (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): TARIN, David [GB/GB]; Honey Cottage, 58 Tree Lane, Iffley, Oxford OX4 4EY (GB). MATSUMURA, Yasuhiro [JP/GB]; 203 Morrell Avenue, Oxford OX4 1NF (GB). (74) Agent: PENNANT, Pyers, Stevens, Hewlett & Perkins, 1 Serjeants's Inn, Fleet Street, London EC4Y 1LL (GB).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PEPTIDE CORRESPONDING TO CD44 EXON 6. ANTIBODIES SPECIFIC FOR SAID PEPTIDE AND USE OF THESE ANTIBODIES FOR DIAGNOSIS OF TUMORS		
(57) Abstract There is marked over-expression of multiple spliced variants of the CD44 gene in tumour compared to counterpart normal tissue. This observation forms the basis of a method of diagnosing neoplasia by analysis of a sample of body tissue or body fluid or waste product. A new exon 6 of 129bp has been located and sequenced. Antibodies specific to the exon have been prepared and are claimed as new compounds suitable for use in the detection of CD44 proteins and for the <i>in vivo</i> imaging and therapy of tumours.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 C12N15/06 C12P21/08 G01N33/577 G01N33/574 G01N33/564
G01N33/68 C07K15/00 A61K39/395 A61K49/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C12N C12P G01N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCIENCE vol. 257, no. 5070 , 31 July 1992 , WASHINGTON DC, USA pages 682 - 685 R. ARCH ET AL. 'Participation in normal immune responses of metastasis-inducing splice variant of CD44.' see figure 3 see page 684, right column ---	1, 2, 5, 13, 16, 19, 20, 23, 25
X	'8th INTERNATIONAL CONGRESS OF IMMUNOLOGY, Budapest, Hungary, August 23-28, 1992' August 1992 , SPRINGER VERLAG , BUDAPEST see M. SALMI et al.: 'Expression of domain 3 containing isoforms of CD44 in man.' (Abstract W-47/I-34) --- -/--	1, 2, 8-12

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

'&' document member of the same patent family

Date of the actual completion of the international search

29 March 1994

Date of mailing of the international search report

21. 04. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016




Authorized officer

Nooij, F

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>THE LANCET vol. 340, no. 8827 , 31 October 1992 , LONDON, GB pages 1053 - 1058 Y. MATSUMURA ET AL. 'Significance of CD44 gene products for cancer diagnosis and disease evaluation.' see the whole document ---</p>	1-26
A	<p>IMMUNOBIOLOGY vol. 183, no. 3/4 , October 1991 , STUTTGART, GERMANY pages 221 - 222 S. SEITER ET AL. 'Expression of variant CD44 transfers the metastatic phenotype and antibodies against variant CD44 inhibit metastatic spread in lymphatic tissue.' see abstract H.17 ---</p>	1-26
A	<p>INTERNATIONAL JOURNAL OF CANCER vol. 46, no. 5 , 15 November 1990 , GENEVA, SWITZERLAND pages 919 - 927 S. REBER ET AL. 'Retardation of metastatic tumor growth after immunization with metastasis-specific monoclonal antibodies.' see the whole document ---</p>	1-26
P,X	<p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA vol. 89, no. 24 , 15 December 1992 , WASHINGTON DC, USA pages 12160 - 12164 G. SCRETON ET AL. 'Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.' cited in the application see abstract see figures 3,4 ---</p>	13
P,X	<p>THE JOURNAL OF CELL BIOLOGY vol. 122, no. 2 , July 1993 , NEW YORK, USA pages 431 - 442 M. SALMI ET AL. 'Regulated expression of exon v6 containing isoforms of CD44 in man: Downregulation during malignant transformation of tumors of squamocellular origin.' see the whole document -----</p>	1-26




1/7

FIG. 1



2/7

FIG. 2



3/7

FIG. 3





FIG. 4





4/7
FIG. 5

FIG. 8



5/7




FIG. 6

6/7




FIG. 7

7/7

Fig. 9 DNA sequence of HIV2(gp32)-CD44 exon 6 fusiongene

ATGAGAGGAT CGCATCACCA TCACCATCAC ACGGATCCAG AATTCCAACA	50
GCAACAGCAG TTGTTGGACG TTGTTAAACG TCAACAGGAA CTGTTGCGTC	100
TGACCGTTTG GGGAAACCAAG AACCTTCAGG CTAGAGTTAC CGCTATCGAA	150
AAATACCTTC AAGACCAGGC TCGTTTGAAC TCCTGGGGTT GCGCTTTTAG	200
ACAGGTTTGT CATACCACGG TACCGTGGGT TAACGACTCT CTGGCTCCAG	250
ACTGGGACAA CATGACCTGG CAGGAATGGG AAAAGCAAGT TCGTTACTTG	300
GAAGCTAACA TCTCCAAATC TCTGGAACAG GCTCAAATCC AGCAAGAAAA	350
AAACATGTAC GAACTGCAGA AGTTGAACTC TTGGGATATC AGATCCCCGG	400
CTACCACTTT GATGAGCACT AGTGCTACAG CAACTGAGAC AGCAACCAAG	450
AGGCAAGAAA CCTGGGATTG GTTTTCATGG TTGTTTCTAC CATCAGAGTC	500
AAAGAATCAT CTTACACAA CAACACAAAT GGCTCCGGCC ACCACTTTGA	550
TGAGCACTAG TGCTACAGCA ACTGAGACAG CAACCAAGAG GCAAGAAACC	600
TGGGATTGGT TTTCATGGT GTTTCTACCA TCAGAGTCAA AGAATCATCT	650
TCACACAACA ACACAAATGG CT	672

Fig. 10 Protein sequence of HIV2(gp32)-CD44 exon 6 fusionantigen

MRGSHHHHHH TDPEF	<u>QQQQQ</u>	<u>LLDVVKRQQE</u>	<u>LLRLTVWGTK</u>	<u>NLQARVTAIE</u>	50
(His),		<u>HIV2 (gp32) (117 aa)</u>			
<u>KYLQDQARLN</u>	<u>SWGCAPRQVC</u>	<u>HTTVPWVND</u>	<u>LAPDWDNMTW</u>	<u>QEWKQVRYL</u>	100
<u>EANISKSLEQ</u>	<u>AQ1QQEKMY</u>	<u>ELQKLNSWDI</u>	<u>RSPATTL MST</u>	<u>SATATETATK</u>	150
		Exon S (3 aa) Exon 6 (43 aa)			
RQETWDWFSW	LFLPSESKNH	LHTTTQMAPA	TTL MST	SATA TETATKRQET	200
		Exon 5 (3 aa) Exon 6 (43 aa)			
WDWFSW	LFLP	SESKNHLHTT	TQMA		224

aa = "amino acid"

PEPTIDE CORRESPONDING TO CD44 EXON 6, ANTIBODIES SPECIFIC FOR SAID PEPTIDE
AND USE OF THESE ANTIBODIES FOR DIAGNOSIS OF TUMORS

5

Background

The present invention is concerned with using
expression of the CD44 gene or part of the CD44 gene to
investigate neoplasia. Such investigation includes
10 taking a tissue, body fluid or other sample from a
patient to perform diagnosis, to give a prognosis or
to evaluate therapy that is already being carried out.
In particular, the invention provides a simple method
for carrying out routine screening for neoplasia using
15 body fluid samples or other samples which can be
obtained non-invasively.

The usual way to diagnose a tumour at present
is by looking at cells or thin slices of tissue down a
microscope, a method which is often very effective but
20 has some important limitations. With a small sample,
diagnosis can be very difficult and often a large
number of cells will not be available, or it is not
desirable or possible to obtain a large sample from
the patient. In as many as 50% of cases a reliable
25 diagnosis cannot be given; it may be that there is no
positive evidence of carcinoma but also no certainty
that the patient is actually free from carcinoma.
More invasive investigation is then required to
establish a diagnosis.

30 Judgment of prognosis also relies on the
appearance of cells when viewed under a microscope.
Generally, the more bizarre-looking the cells in a
primary tumour, the more likely they are to
metastasise later on but the correlation is by no
35 means absolute. It would clearly be an advantage to
be able to predict more accurately whether or not

- 2 -

metastasis is likely to occur in order to judge what will be the most effective treatment.

The human CD44 gene codes for a family of variably glycosylated cell surface proteins of different sizes, the numerous functions of which are not yet fully established, but which share epitopes recognised by the CD44 monoclonal antibody (mAb). It is known to consist of a standard portion which is expressed in haemopoietic cells and many other cell types and into which the products of additional exons may be spliced in various combinations to produce different proteins. This is a well recognised mechanism in eukaryotes for producing several often functionally unrelated proteins from the same gene, and is known as alternative splicing.

Two common CD44 isoforms have so far been purified and characterised (Stamenkovic *et al.* 1989), namely i) a 90kD form consisting of a central 37kD core which is heavily glycosylated and ii) a 180kD form which has 135 extra amino acids inserted into the proximal extra-membrane domain and is even more heavily glycosylated. Immuno-cytochemical and immuno-precipitation studies have shown that both are widely distributed in many different cells and tissues. The former is known as the haemopoietic or standard form which is present on circulating leukocytes, bone marrow cells and numerous other cell types. The other, known as the epithelial variant, is detectable on several epithelial cell types. Both are believed to function as receptors mediating homotypic and heterotypic adhesive interactions, attaching cells to each other or to adjacent extracellular scaffolding.

Some time ago, some of the CD44 epitopes recognised by the mAb Hermes-3 were identified as constituting the peripheral lymph node receptor enabling circulating lymphocytes to recognise and

- 3 -

traffic through peripheral lymph nodes. Further mAbs to this antigen later became available and Stamenkovic et al. (1989) used one of them to clone a cDNA sequence coding for the standard form of the molecule from an expression library in COS cells. They additionally found, by Northern blotting, that this gene was expressed not only by lymphoid cells, but also by a variety of carcinoma cell lines and a representative sample of solid carcinomas, amongst which two colonic carcinomas appeared to express more than normal colonic epithelium.

Birch and colleagues (1991) reported that melanoma cell clones which strongly expressed the 80-90kD form of the CD44 antigen, recognised by the Hermes-3 antibody, were substantially more metastatic in nude mice than clones which expressed it weakly. Sy et al. (1991) described a moderate increase in metastatic capability of human lymphoma cells in nude mice, after the cells were transfected with the standard CD44 gene, but not after transfection with a construct coding for the epithelial variant. Gunthert et al. (1991) obtained results indicating that a variant form of the lymphocyte homing receptor, recognised by a new antibody raised to the rat CD44 antigen, is required for metastatic behaviour of rat pancreatic adenocarcinoma cells. Using this antibody they cloned a cDNA sequence corresponding to the variant form of CD44 and found that it contained previously unidentified exons. Transfection of a non-metastatic clone from the same cell line with a construct designed to over-express this cDNA sequence unique to the metastatic counterpart, appeared to induce metastatic behaviour (Gunthert et al., 1991).

In view of these findings it became of interest to know whether other cultured metastatic and non-metastatic human tumour cell lines, of various

histogenetic origins, expressed CD44 products differentially. The expression of genes in cells or tissues can be studied most efficiently and sensitively by making cDNA from cellular messenger RNA and
5 amplifying regions of interest with the polymerase chain reaction, using specific oligonucleotide primers chosen to anneal preferentially to portions of the cDNA corresponding to the gene products. However, subsequent work by Hofmann et al. (1991) and the
10 present applicants using this approach provided results which showed that CD44 expression did not regularly and reliably correlate with the metastatic capability or even tumour forming ability of these cultured cell lines in nude mice. At about this time, three separate
15 groups (Hofmann et al., 1991, Stamenkovic et al., 1991 and Jackson et al., 1992) published sequence data on further splice variants they had found being expressed by this gene in various human cell lines.

20 The Invention.

The present invention results from a surprising discovery resulting from studies examining the expression of various parts of the CD44 gene in fresh tissue and body fluid samples from patients with
25 tumours of the breast and colon and from their metastases. The results indicate sharp and clear differences in CD44 expression between tissues from i) metastatic (malignant) tumours, ii) non-metastatic locally invasive tumours and benign tumours
30 and iii) normal tissue. The distinction between groups i) and ii) is important for judgment of therapy and that between groups ii) and iii) is important for early diagnosis and screening.

Part of this invention forms the subject of
35 our International patent application PCT/GB93/01520 filed 20 July 1993, which provides in one aspect a

method of diagnosis of neoplasia, which method comprises analysing the expression of the CD44 gene in a sample.

In a particular embodiment, that application provides a method of assaying a sample for products of the CD44 gene or part thereof which method comprises making cDNA from messenger RNA (mRNA) in the sample, amplifying portions of the complementary DNA (cDNA) corresponding to the CD44 gene or part thereof and detecting the amplified cDNA, characterised in that the amplified cDNA is used in diagnosis of neoplasia.

The diagnosis of neoplasia may refer to the initial detection of neoplastic tissue or it may be the step of distinguishing between metastatic and non-metastatic tumours. References to the term "diagnosis" as used herein are to be understood accordingly.

The method is particularly applicable to the diagnosis of solid tumours particularly malignant tumours e.g. carcinomas. The sample on which the assay is performed is preferably of body tissue or body fluid; and not of cells cultured in vitro. The sample may be a small piece of tissue or a fine needle aspirate (FNA) of cells from a solid tumour. Alternatively, it may be a sample of blood or urine or another body fluid, a cervical scraping or a non-invasively obtained sample such as sputum, urine or stool.

The cDNA may be detected by use of one or more labelled specific oligonucleotide probes, the probes being chosen so as to be capable of annealing to part of the amplified cDNA sequence. Alternatively, labelled oligonucleotide primers and/or labelled mononucleotides could be used. There are a number of suitable detectable labels which can be employed, including radiolabels.

Reference is directed to the accompanying

drawings, in which:-

Figures 1 to 5 are autoradiographs showing the results of various experiments reported below,

Figure 6 is a map of the CD44 gene showing
5 exons, probes and primers. The numbering of the exons corresponds to that used by G. R. Screaton et al. 1992),

Figure 7 is the nucleic acid sequence of Exon 6 (shown in Figure 6), the corresponding amino acid
10 sequence being also shown, and

Figure 8 is a set of autoradiographs showing the results of another experiment.

Figure 9 is the DNA sequence of HIV2(gp32)-CD44 exon 6 fusion gene.

15 Figure 10 is the protein sequence of HIV2(gp32)-CD44 exon 6 fusion antigen.

Figure 6 is a map of the CD44 gene showing exons 6 to 14. The basic or standard protein can theoretically be modified by the insertion of
20 transcripts from any, some, or all of these 9 extra exons. Exon 6 was unknown at the priority date of this patent application, and constitutes a further aspect of the invention. Exon 6 is over-expressed in tumours but not in normal tissues, and is located in the vicinity
25 of exons 7 to 9. The sequence of exon 6 is given in Figure 7. It contains 129 base pairs and is flanked on the 5'-side by the standard CD44 sequence, and on the 3'-side usually by exon 7.

In contrast to Exons 9 to 11, the products of
30 Exon 6 (the newly-sequenced Exon) are only barely detectable in samples of normal tissues. This suggests that Exon 6 will be of particular value in the diagnosis of neoplasia.

In another aspect, that application provides
35 as new compounds, the nucleic acid sequence of Exon 6 as shown in Figure 7, characteristic fragments thereof,

sequences which are degenerated and/or represent allele variations, the homologous nucleic acid sequences, and probes, primers and other reagents capable of hybridising with the sequences or homologues. These
5 compounds and reagents will all be useful in the method described above.

In accordance with the present invention the peptide sequence corresponding to CD44 exon 6 as shown in Figure 7, its allele variations and secondary
10 modifications thereof and characteristic fragments thereof can be used to generate antibodies useful for the in vitro and in vivo diagnosis. Said antibodies are specific to the peptide corresponding to CD44 exon 6 as shown in Figure 7, its allele variations and
15 secondary modifications thereof and characteristic fragments thereof i.e. these antibodies bind to this peptide and possess a low cross-reactivity towards other related CD44 proteins and other proteins. Said antibodies may be monoclonal or polyclonal. The
20 antibodies may be generated by using the entire peptide sequence corresponding to CD44 exon 6 as shown in Figure 7 as an antigen or by using short peptides preferably of a minimum length of six amino acids encoding portions of the peptide sequence corresponding
25 to CD44 exon 6, as antigens. The peptides used as antigens can be produced recombinantly or chemically by methods known in the art. The peptide antigens according to the invention can for example be synthesized according to Merryfield, JACS 85 (1964),
30 2146. For immunogen synthesis these peptides can be coupled to a carrier molecule for example keyhole limpet hemocyanin (KLH) or bovine serum albumin (BSA). If a biotinylation is required this can for example be carried out according to PNAS USA 80 (1983), 4045.
35 For the expression of the peptide corresponding to CD44 exon 6 or its allele variations

- 8 -

in a procaryotic host it is preferred to prepare a fusion gene of CD44 exon 6 or its allele variations with a gene which possess a high expression level in this host. For example a part of the gene encoding for the protein gp 32 of HIV 2 is suitable for E. coli. Thereby a fusion protein which possesses as a part the peptide sequence according to Exon 6 or its allele variations is obtained. It is also preferred to increase the number of the peptide epitopes corresponding to CD44 exon 6 in such a fusion protein for example by duplicating the CD44 exon 6 gene in the fusion gene.

Polyclonal antibodies directed against the peptide sequence corresponding to CD44 exon 6, its allele variations and secondary modifications thereof and characteristic fragments are prepared by injection of suitable laboratory animal with an effective amount of a peptide or antigenic component, collecting serum from the animal, and isolating specific antibodies by any of the known immuno absorbent techniques. Although the polyclonal antibodies produced by this method are utilizable in any type of immunoassay, they are generally less favoured because of the potential heterogeneity.

The use of monoclonal antibodies in the in vitro diagnostic test is particularly preferred because large quantities of antibodies all of similar specificity may be produced. The preparation of hybridoma cell lines for monoclonal antibody production is done by fusion of an immortal cell line and the antibody producing lymphocytes. This can be done by techniques which are well known in the art (see for example Harlow, E. and Lane, D., Antibodies: A Laboratory Manual, Cold Spring Harbour Press 1988, Bessler et al. Immunobiol. 170 (1985), 239 - 244, Jung et al., Angew. Chemie 97 (1985), 883 or Cianfriglia et al., Hybridoma Vol. 2, (1983), 451 - 457).

- 9 -

The following hybridoma cell lines which are producing monoclonal antibodies directed against the expression product of CD44 exon 6 as shown in Figure 7 or a fragment thereof e. g. a characteristic epitope were deposited on 16. November 1993 under the Budapest Treaty at the DSM (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-3300 Braunschweig, Federal Republic of Germany:

MAK<CD44>M-1.1.12

10 MAK<CD44>M-2.42.3

MAK<CD44>M-4.3.16

For MAK<CD44>M-1.1.12 a synthetic peptide corresponding to amino acids 9 - 23 , for MAK<CD44>M-2.42.3 a synthetic peptide corresponding to amino acids 29 - 43 and for MAK<CD44>M-4.3.16 a synthetic peptide corresponding to amino acids 1 - 13 of the CD44 exon 6 peptide having the amino acid sequence shown in Figure 7 was used. The antibody produced by the cell line MAK<CD44>M-1.1.12 shows a specificity to tumor tissue of lung, colon and bladder and for cells of the cell line ZR75-1 (human breast carcinoma - ATCC CRL 1500) as detected by immunohistochemistry. A specific reaction means that a strong reaction is observed with the tumor tissue whereas normal tissue shows only a weak reaction. In the same system the antibody produced by the cell line MAK<CD44>M-4.3.16 shows specificity towards tumor tissue of colon and ZR75-1 cells.

The presence of the CD 44 protein or the peptide sequence according to CD44 exon 6 in a sample can be detected utilizing antibodies prepared as described above either monoclonal or polyclonal in virtually any type of immunoassay. A wide range of immunoassay techniques are available as can be seen by reference to Harlow, et al. (Antibodies: A Laboratory Manual, Cold Spring Harbour Press 1988). This of course includes both single-site and two-site, or "sandwich"

of the non-competitive types, as well as competitive binding assays. Sandwich assays are among the most useful and commonly used assays. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Examples for those assays are radio immunoassays, enzyme immunoassays or immunofluorescent assays such as FPIA or electrochemiluminescent assays, immunoassays using direct labels such as dye particles (e.g. gold sol particles), homogeneous immunoassays such as CEDIA or EMIT or turbidimetric and nephelometric methods such as latex particle agglutination assays. It is possible to use two antibodies according to the invention in a sandwich assay. In this case these two antibodies must bind to different epitopes or sites of the peptide sequence according to CD44 exon 6. These antibodies could for example be prepared by using two different synthetic peptides as immunogens corresponding to different characteristic fragments of the peptide corresponding to CD44 exon 6. It is also possible to use only one antibody according to the invention in a sandwich assay. The other antibody could be an antibody to the other peptides corresponding to other CD44 exons or to the standard form of CD44. Such antibodies are known in the art.

It is possible to use for example urine, whole blood, cervical smears, stool, tissue for example biopsies, sputum or cells as sample. In most cases the CD44 protein could be detected in its native form. Preferably the CD44 protein is denatured prior to or during its detection because some of the antibodies according to the invention preferably bind to epitopes which are linear or which are hidden within the CD44 molecule in its native form. As a denaturation method any method known in the art such as treatment with detergent or chaotropic agents is suitable. In some

- 11 -

cases the adsorption of the CD44 molecule to a solid phase leads to a partial denaturation which is sufficient for the binding of the antibody.

Although CD44 proteins are expressed on most
5 cell types it was found that with the use of the antibodies according to the invention a differentiation between tumor tissue and normal tissue is possible in most cases. The antibodies therefore could be used in cancer diagnosis. Preferably the antibodies could be
10 used for the diagnosis for cancer of tissue of colon, bladder or lung. For example with the antibody obtainable from the hybridoma cell line MAK <CD44>M-1.1.12 a strong reaction is observed in immunohistochemistry with colon, bladder or lung
15 carcinoma tissue whereas normal tissue of this origin gives only a weak reaction.

It is also possible to utilise the antibodies according to the invention in immune complex analysis for example in a method according to Wong et al., Arch.
20 Surg. 125 (1990), 187 - 191. Thereby the detection of tumor-associated immune complexes of CD44 protein or characteristic parts thereof and autoantibodies is possible.

The peptide antigens according to the
25 invention can also be used as a standard compound in immunological tests for the quantitative determination of CD 44. The invention therefore in addition concerns the use of the peptide antigens according to the invention as a standard in an immunological test for
30 the determination of CD 44. In certain cases, for example in agglutination tests, it may be advantageous to bind several peptides according to the invention with the same or different sequences to a carrier molecule. The peptides according to the invention can
35 also be used as a binding partner for the antibody according to the invention in a competitive

immunoassay. In this case the peptides are labeled or bound to a solid phase directly or indirectly via two specific binding partners such as (strept)avidin/biotin by methods known in the art.

5 Another aspect of the invention is a test kit containing at least one antibody which is directed against the peptide corresponding to CD44 exon 6 having the amino acid sequence as shown in Figure 7, its
10 allele variations or secondary modifications thereof or characteristic fragments thereof among the other compounds which are necessary for the immunoassay such as buffers, detergents, stabilizers, solid phases etc. If required the peptide antigens according to the
15 invention as a standard could also be included.

20

25

30

35

40

In still another important aspect, this invention provides a means for therapy and in vivo imaging of tumours. Agents useful for this can be manufactured according to the state of the art. The data obtained from studies examining the expression of various parts of the CD44 gene in samples from patients with malignant diseases surprisingly show a significant overexpression of exon 6 of the variable part of CD44. The relative abundance of CD44 splice variants containing exon 6 in malignant tumours as compared to normal tissue and the increased amount of CD44 proteins containing the peptide sequence encoded by exon 6 on the surface of tumour cells as compared to normal tissue opens the possibility to use the exon 6 encoded peptide sequence as a tumour specific antigen for therapy, diagnosis both in vivo and in vitro, and in vivo imaging.

Preferably, monoclonal antibodies (Köhler and Milstein (1975), Nature 156, 495-497) or their derivatives will be used for diagnostic and therapeutic purposes. In this invention, monoclonal antibodies to epitopes encoded by exon 6 of CD44 are provided. Furthermore, data are presented, showing selective binding of these antibodies to tumour cells.

The antibodies according to the invention recognize the peptide corresponding to CD44 exon 6 having the amino acid sequence shown in Fig. 7, its allel variations and phosphorylation and glycosylation products and characteristic fragments thereof. Such antibodies are specific to the peptide corresponding to CD44 exon 6 also in the presence of other peptides which correspond to other CD44 exons. For therapeutic purposes this specificity is defined to the effect that the antibody according to the invention binds only to a little extent to proteins other than the protein encoded by exon 6. This unspecific binding must be so

little as to ensure that no considerable damage will be caused to healthy cells when the antibodies according to the invention are used for tumour therapy or in vivo diagnosis.

5 The antibodies can be used as whole antibodies, fragments thereof (e.g. Fv, (Fv)₂, Fab, Fab', F(ab)₂, chimeric, humanized or human antibodies as long as they are binding the exon 6 protein in a suitable manner. Short-chain antibody fragments
10 containing only the CDR regions or parts thereof conferring the specific binding to the exon 6 peptide are also suitable, especially if the antibody is a labelled one.

 Here the antibodies can be used as a whole
15 for therapy of malignant diseases (Hale et al., Lancet 2 (1988) 1394-1399; Cobbold et al., Prog. Clin. Biol. Res. (1990) 333, 139-151). In another approach, the antibody or part of it is conjugated or translationally fused to a toxin molecule (immunotoxin), thus effecting
20 specific killing of tumour cells (Brinkmann et al. 1991, Proc. Natl. Acad. Sci. USA 88, 8616-8620; Pastan et al. (1991), Cancer Res. 51, 3781-3787; FitzGerald and Pastan (1989), J. Natl. Cancer Inst. 81, 1455-1461). In another preferred embodiment of the
25 invention, bispecific antibodies are used for tumour therapy (Bonino et al. (1992), BFE 9, 719-723), which may be constructed by in vitro reassociation of polypeptide chains, by hybrid hybridoma generation or by construction of diabodies (Holliger et al. (1993),
30 Proc. Natl. Acad. Sci. USA 90, 6444-6448; Holliger and Winter (1993), Current Opin. Biotechnol. 4, 446-449).

 In addition, antibodies coupled to radioactive or fluorescent substances are preferred for detection and treatment of tumours, including
35 carcinomas of the respiratory, gastrointestinal and urogenital system as well as ocular and skin cancers

- 15 -

(Profio (1988), Proc. Soc. Photoopt. Instr. Eng. 907, 150-156; Jiang et al. (1991), J. Natl. Cancer Inst. 83, 1218-1225).

For prevention of an immune response, it is preferred to use antibodies which resemble as closely as possible antibodies of human origin (Glassy and Dillman (1988), Mol. Biother. 1, 7-13). Such antibodies are, for example, chimeric or humanized (CDR-grafted) antibodies. Such antibodies usually are manufactured from a rodent monoclonal antibody (see e.g. for review: Morrison (1992), Annu. Rev. Immunol. 10, 239-265; Winter and Milstein (1991), Nature 349, 293-299). In a specifically preferred embodiment of the invention, tumour specific human antibodies (Borrebaeck et al. (1988), Proc. Natl. Acad. Sci. USA 85, 3995-3999; Borrebaeck (1988), Immunol. Today 9, 355-359) are used for therapeutic purposes. In addition, it is specifically preferred to prepare human Mabs via phage display libraries, as is described, for example, by Griffith et al., EMBO J. 12 (1993) 725-734.

It is specifically preferred to use, for therapeutic purposes, antibodies which impart effector functions (ADCC, CDC) (Bruggemann et al., J. Exp. Med. 166 (1987) 1357-1361). Particularly preferably, a human isotype IgG 1 antibody is used.

With regard to immunotoxins, it is preferred to couple the antibody according to the invention to a toxin, such as, for example, Pseudomonas exotoxin, Diphtheria toxin or other toxins (FitzGerald and Pastan (1989)). It is also preferred to couple the antibodies to chemotherapeutics, such as, for instance doxorubicin, or to radioactively labelled substances which have a cytotoxic effect.

Conjugates of the antibodies according to the invention, in particular of human antibodies, for in vivo imaging, using, for instance, radioactive or

SUBSTITUTE SHEET

- 15/1 -

fluorescent substances, are also preferred.

The therapeutic compounds of this invention may be administered parenterally, such as intravascularly, intraperitoneally, subcutaneously, intramuscularly, using forms known in the pharmaceutical art. The active drug components of the present invention are used in liquid, powdered or lyophilized form and may be combined with a suitable diluent or carrier, such as water, a saline, aqueous dextrose, aqueous buffer, and the like. Preservatives may also be added.

Regardless of the route of administration selected, the compounds of the present invention are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those skilled in the art. The compounds may also be formulated using pharmacologically acceptable acid or base addition salts. Moreover, the compounds or their salt may be used in a suitable hydrated form.

Regardless of the route of administration selected, a non-toxic but therapeutically effective quantity of one or more compounds of this invention is employed in any treatment. The dosage regimen for treating is selected in accordance with a variety of factors including the type, age, weight, sex and medical condition of the patient, type of tumour, the route of administration and the particular compound employed in the treatment. A physician of ordinary skill can readily determine and prescribe the effective amount of the drug required regarding known antibody therapy approaches (Hale (1988), Cobbold (1990)). In so proceeding, the physician could employ relatively low doses at first, and subsequently, increased dose until a maximum response is obtained.

35

SUBSTITUTE SHEET

The chaotic over-expression of multiple spliced variants of the CD44 gene in tumours, implies that a particular exon may or may not be over-expressed (or expressed at all) by a particular tissue sample.

5 An immunoassay using an antibody to the peptide expressed by any single exon may therefore give misleading results. This invention therefore includes use, for the immunological diagnosis of neoplasia, of a mixture of antibodies to two or more, and preferably to
10 all nine, of the CD44 exons.

In the examples which follow it was found that expression of the human CD44 gene was consistently and distinctively increased in various solid tumours relative to normal tissues. Malignant (i.e. already
15 metastatic) tumours differed from locally invasive and benign ones in the pattern and magnitude of changes seen. The study was performed on samples from 46 tumours of which 44 were locally invasive, or metastatic and 2 were benign. Analysis of CD44
20 expression was performed by using PCR to amplify cDNA made by reverse transcription of RNA extracted from fresh surgical biopsy samples. By choosing oligonucleotide primers which specifically anneal to certain portions of the CD44 gene, it is possible to
25 amplify portions of the gene which, from these results, are of diagnostic and prognostic interest.

The strong association found here, between altered CD44 expression and neoplasia, need not imply that any of the individual exons of the gene are
30 expressed only in neoplasia or in progression to metastatic malignancy. Evidence accrued in many laboratories in recent years (see Knudson 1985, Tarin 1992, Hayle et al 1992 for reviews) indicates that these pathological processes are probably the
35 consequences of disturbed regulation of genes coding for normal cellular activities such as cell

- 17 -

proliferation and migration. Therefore it seems unlikely that any gene, or portion of a gene, has the sole function of programming neoplasia or metastasis.

The finding in the present study of
5 transcripts from exon 10/11 in normal tissues, indicates that this exon is not exclusively concerned with metastatic activity, even though there is marked increase in the number and signal intensity of bands hybridising with radiolabelled probe E4 in the PCR
10 products from tumours capable of metastasis. Other supporting events are therefore believed to be required for CD44 exon 10/11 expression to result in metastatic behaviour. Nevertheless, the observation that transcripts from this exon were over-expressed in
15 samples from metastatic tumours promises to be a very useful indicator of prognosis.

It is not expected that further research will find that the natural (non-mutated) products of any individual exon will be uniquely present in tumour
20 cells and not in normal counterparts. Instead, it is likely that an abnormal pattern of gene activity consisting of over-expression and inappropriate combination of products of a gene, such as that reported here for the CD44 locus, could play a part in
25 malignancy. These changes may themselves be required for malignant conversion, or be the consequence of other genetic disturbances causing such a conversion. Even so, without resolving this issue, an observer using these techniques can obtain information relevant
30 to assigning a sample to neoplastic or non-neoplastic categories.

EXAMPLES

Method

35 Fresh tissue samples, 0.5 - 1 cm diameter, were obtained from surgical resection specimens removed

at therapy of 34 patients with breast tumours and colon tumours. The samples were snap-frozen in liquid nitrogen within ten minutes of arrival in the pathological specimen reception area and kept in liquid nitrogen until use. Portions of lymph node metastases and blood-borne metastases were also collected, if present, in the tissue resected for diagnosis. Normal breast tissue, normal colon mucosa, normal lymph node adjacent to the tumour in the breast and normal liver were also collected from the surgically resected samples and from other samples removed for non-neoplastic conditions. Normal peripheral blood leukocytes were obtained from 10 volunteers and bone marrow from 3 volunteers. The histological features of the tumours and their clinical stages were as described in Table 1.

Total cellular RNA extraction from tissue samples was performed according to the method described by Chomizynski and Sacchi (1987). Extraction from fluid samples was by use of the Microfasttrack kit marketed by Invitrogen. cDNA synthesis and subsequent amplification by the polymerase chain reaction (PCR) was performed using the SuperscriptTM preamplification system (BRL Life Technologies Inc., Middlesex, UK) with buffers and reagents supplied in this kit. In brief, this involves an initial step of first strand cDNA synthesis with reverse transcriptase, using sample RNA as the template and supplied nucleotide triphosphates. For subsequent PCR each sample was overlaid with oil and heated at 94°C for 5 minutes to denature nucleic acid; 30 cycles of PCR were then conducted with the following cycle parameters: 94°C for 1 m, 55°C for 1m, 72°C for 2 m. Negative controls in which there was no template cDNA in the reaction mix, were routinely run with each batch. The primers and probe sequences were devised, using information from the published sequence

- 19 -

for human CD44 cDNA (Hofmann et al., 1991, Stamenkovic et al., 1991, Jackson et al., 1992) (Figure 6) were as follows:

5 P1 = 5'GACACATATTGCTTCAATGCTTCAGC

P4 = 5'GATGCCAAGATGATCAGCCATTCTGGAAT

P1 is located with its origin 324bp upstream from the insertion site in the standard CD44 molecule (between nucleotides 782 and 783 in the sequence published by Stamenkovic et al., 1989) and P4 is 158bp downstream of this site. These primers produce a PCR fragment of 482bp if a sample expresses standard CD44 (so-called haemopoietic CD44), 878bp for the epithelial form of CD44 and several other bands, if a sample contains alternatively spliced transcripts. 10 µl of each PCR product was electrophoresed in a 1.2% agarose gel and transferred to Hybond N⁺ (Amersham UK, Little Chalfont, UK) nylon membranes for hybridisation with oligonucleotide probe E4 (=5'TGAGATTGGGTTGAAGAAATC-3'), see Figure 6. Blotting and autoradiography were performed to improve sensitivity of detection and resolution. The probe was radiolabelled with $\gamma^{32}\text{P}$ -ATP in the presence of polynucleotide kinase. After prehybridisation, hybridisation was performed in 10% dextran, 6 x NET, 5 x Denhardt solution, 0.5% NP40 and 100 µg/ml salmon sperm DNA at 42°C overnight. The filter was then washed twice in 2 x SSC, 1 x SSC and 0.5% SSC with 0.1% SDS at 42°C sequentially for 15 minutes each. Filters were exposed to Kodak X-ray film for 2-16 hours. After this, the filters were boiled in 0.5% SDS for stripping the probe and rehybridised with another radiolabelled probe, namely P2 (=5'CCTGAAGAAGATTGTACATCAGTCACAGAC) we designed to anneal to the standard portion of the CD44 (Figure 6). The conditions used for hybridisation, washing and autoradiography were the same as above.

- 20 -

Calibration of the sensitivity of the method, for detection of small numbers of cells was performed as follows: total peripheral blood leukocytes (PBL) were purified from 20ml whole blood by lysis of packed red blood cells by addition of ammonium chloride buffer (1ml packed cells to 50mls lysis buffer) and subsequent centrifugation 15 minutes later. The white cell pellet was divided into 4 tubes which were seeded respectively with 0µl, 1µl, 10µl and 100µl of a suspension of HT29 colon carcinoma cells (5000 cells per ml). Total RNA was then extracted and each tube yielded approximately 20µg. cDNA synthesis was performed, as described above on 4µg aliquots of the RNA obtained from each tube representing 0, 1, 10 and 100 tumour cells per aliquotted sample respectively. The PCR was performed on these samples and on positive (tumour cells only) and negative (no DNA) controls using primers D1 and D5 which were designed by us to anneal specifically to exons 7 and 14 in Figure 6. We know from previous studies that HT29 cells express both exons, and others, in a pattern easily distinguishable from PBL and chose the oligonucleotide primers D1 and D5 because we wished to increase sensitivity by shortening the segment to be amplified. It was also reasoned that use of these primers would circumvent the problem of using primers P1 and P4 for this specific purpose because the majority of these would be soaked up by annealing to the standard portion of the gene. PCR cycle parameters, blotting, probing and washing conditions were as described above. The oligonucleotide sequence used for probing was ³²p labelled E4.

35 General Overview of Results

As the primers (P1 and P4) amplify across the

splice product insertion site it is clear that the intervening part of the standard molecule will be amplified, in addition to any alternatively spliced variants which contain transcripts from the additional
5 exon domains. Hence the total number of products which could conceivably be detected with a probe (e.g. P2) to the standard form considering all possible combinations of the sequences identified from this locus, is large. Using probe E4, 16 of these combinations, namely those
10 containing E4 transcripts from exon 11, could potentially be visualised as bands of different molecular sizes resolved by electrophoresis. In practice the full range of possible combinations was not detected in these results, but several (up to 9)
15 alternative splice variants were seen in neoplastic tissues hybridised with each probe. Normal tissues from the breast, colon and lymph nodes did express some E4-containing transcripts (Figures 1 and 3), in addition to the standard molecule (Figures 2 and 4),
20 but peripheral blood leukocytes (Figure 5) and liver (Figure 4) detectably expressed only the latter with this combination of probes and primers. The details are presented below:

25 EXAMPLE 1

Breast Tissue Samples

The results obtained in the study of breast tissue samples are illustrated in Figures 1 and 2. Metastatic tumour deposits and their corresponding
30 primary tumours from all cases over-expressed several alternatively spliced products containing transcripts from exon 11 (Figure 1a). At least 8 separate bands were frequently seen together with a consistent doublet at 1500bp and 1650bp present in all tumours. Normal
35 breast tissue and normal lymph node produced two bands (1150bp and 860bp) with this probe. The doublet

- 22 -

mentioned above was not seen in any normal sample.

The differences between the number, and size of the bands and the intensity of signal from the bound probe, between tissues in normal and malignant

5 categories, was obvious in all samples examined. For occasional samples it was necessary to expose the filter to the X-ray film for longer, to see the distinctive differences, but this finding was confirmed in every case studied.

10 Samples from locally invasive tumours with no associated clinical evidence of metastasis and from the two fibroadenomas also over-expressed splice products containing transcripts from exon 10/11 relative to
15 normal tissues, but the extent of this was easily distinguished from the results obtained with malignant tumours and their metastases. Distinction from the patterns seen in normal tissues was also easy (Figure 1b). However, a single sample gave a similar result to malignant tumours (lane 14) (see below). The two
20 fibroadenomas showed band patterns that were similar to those from non-metastatic carcinomas and the sample from a case of cystic disease of the breast resembled the pattern for normal non-neoplastic breast tissue. This is the first instance of definitive diagnosis by
25 this method. The piece of tissue was provided by the duty pathologist as being from a benign tumour, namely a fibroadenoma, on macroscopic appearance at initial inspection with the naked eye. It was then characterised as definitely non-neoplastic after PCR
30 amplification of its cDNA, and subsequent microscopical examination of the tissue confirmed this.

To confirm that the differences seen with probe E4 are valid and not technical artifacts, the results obtained when the same filter was hybridised
35 with probe P2 are shown in Figure 2. This shows that i) all tissues examined expressed the standard form of

- 23 -

the gene, ii) other exon splice products, not containing transcripts from exon 10/11, were present in tumours and metastases and iii) that the differences described above are not due to unequal loading of tracks in the various panels and lanes on this composite filter, but resulted from alternative splicing. All conditions in this experiment were the same as those in hybridisation with E4, except the exposure time of the filter to X-ray film (10 hours exposure for Figure 1, versus 1.5 hours for Figure 3).

EXAMPLE 2

Colon Samples

The findings in colon carcinoma were identical to those in breast carcinoma. Thus, in all cases the colon carcinoma tissues showed increased number of more intensely labelled, larger molecular weight bands with probe E4 (Figure 3) than normal colonic mucosa and other normal tissues. As with breast carcinomas, hybridisation with probe P2 showed no differences in the degree of expression of the standard form of the molecule (Figure 4).

EXAMPLE 3

Calibration of the Sensitivity of the Method

Examination of autoradiograms of PCR products of peripheral blood leukocytes seeded with known numbers of HT29 colon carcinoma cells showed the presence of additional bands characteristic of tumour cells, down to a level of 10 tumour cells in a sample of 10^7 leukocytes. By fine-tuning the conditions of the assay it is considered possible to detect a single tumour cell in 10ml of blood.

In the series described above, all samples of neoplastic tissue showed over-expression of

alternatively spliced products of the CD44 gene and none of the samples from non-neoplastic tissue did so. Therefore, there was complete correspondence between normal or neoplastic origin of a sample and pattern of CD44 expression. In one instance, a tumour removed from a patient (patient B16, lane 14 in Figure 1A) with no current clinical evidence of metastasis, was found to have a pattern of expression indicating metastatic capability. At present it is not possible to know whether this is a false positive result, or a sign of imminent metastasis. This patient is currently under observation in the follow-up clinic.

EXAMPLE 4

We have designed and synthesised oligonucleotide primers according to our current findings, as follows:-

Primer P1 = 5'-GACACATATTGCTTCAATGCTTCAGC (458-484)
Primer P2 = 5'-CCTGAAGAAGATTGTACATCAGTCACAGAC (488-518)
Primer P3 = 5'-TGGATCACCGACAGCACAGAC (746-767)
Primer P4 = 5'-GATGCCAAGATGATCAGCCATTCTGGAAT (912-941)
for standard part (Stamenkovic 1989)
Primer E1=5'-TTGATGAGCACTAGTGCTACAGCA
Primer E2=5'-CATTTGTGTTGTTGTGTGAAGATG
Primer E3=5'-AGCCCAGAGGACAGTTCCTGG (534-554)
Primer E4=5'-TGAGATTGGGTTGAAGAAATC (558-578)
Primer E5=5'-TCCTGCTTGATGACCTCGTCCCAT (585-608)
D1 : 5' GAC AGA CAC CTC AGT TTT TCT GGA (63-86)
D5 : 5' TTC CTT CGT GTG TGG GTA ATG AGA (888-911)
for the exons (Hofmann 1991). E1 and E2 are on exon 6.

Fresh tissue samples 0.5-1 cm in diameter were obtained from surgical resection specimens or at autopsy. All samples used in this work were obtained from the residue of tissue remaining after diagnostic samples had been taken, and which would otherwise have been discarded. The samples were snap-

- 25 -

frozen in liquid nitrogen within ten minutes of arrival at the pathological specimen reception area and kept frozen in nitrogen until use. cDNA was synthesised with viral reverse transcriptase using 5 µg of total cellular RNA as template, followed by PCR with Primer P1 and Primer P4. PCR amplification, electrophoresis and hybridisation were performed under standard conditions.

When the PCR products were hybridised with radiolabelled E2 or E4, all samples from carcinomas over-expressed several splice variants, but the pattern of bands seen with each probe was different. Hence, the oligonucleotide probe for Exon 6 products is very effective in distinguishing neoplastic from non-neoplastic samples, but not significantly more sensitive than E4, at least on samples from solid tissues, but is possibly useful for detecting organ of origin of a disseminating metastatic cell or an established metastasis. Subsequently, the same filters were stripped and hybridised with P2 probe to show that all samples, including normal tissues, produced the standard portion of CD44. This confirmed that the differences observed between the results obtained with normal and tumour samples, probed with E2 and E4, were not due to unequal loading of PCR products. The cumulative results are summarised in Table 3 which indicates that these changes are seen in a wide range of common cancers.

30

35

- 26 -

Table 3

Type of Tissue	No. of Patients/ Volunteers	No. Showing Increased Splice Variants
5 Neoplastic	47	46
Breast Cancer	21	21
Colon Cancer	13	13
Bladder Cancer	6	6
Stomach Cancer	1	1
Thyroid Cancer	1	1
Fibroadenoma	2	2
10 Prostate Cancer	3	2
Non-Neoplastic	39	0
Normal Breast	9	0
Cystic Disease of Breast	1	0
Normal Colon	9	0
Crohn's Disease	1	0
15 Ulcerative Colitis	1	0
Appendicitis	1	0
Normal Bladder	4	0
PBL	10	0
Bone Marrow	3	0

20

We have also examined some malignant tumours of bone muscle and observed a similar pattern, of marked over-expression of multiple spliced variants, in the osteosarcoma.

25

EXAMPLE 5Cancer Diagnosis by PCR Assay of Clinically-Harvested Urine Samples

Approximately 50 ml naturally-voided urine were obtained from each person and transported to the laboratory as speedily as possible. Specimens from 90 patients were examined: 44 from patients with biopsy-proven bladder cancer, 46 from patients with non-neoplastic inflammation of the bladder (cystitis) and from normal volunteers. One ml of each urine sample was removed after thorough mixing and submitted for

cytological examination. Another 1 ml of urine was checked by Fluorescein diacetate-ethidium bromide staining to assess the viability of cells in the sample. The remainder of the urine was centrifuged at 2000rpm for 10 minutes and the cell pellet was kept at -70°C until use. mRNA extraction was performed with oligo dT cellulose tablets (Invitrogen). cDNA was synthesised with AMV reverse transcriptase (Invitrogen). The completed cDNA solution was divided equally into two tubes, one being for PCR with E1 and E5, to amplify the particular cDNA transcript, which we have found to be of diagnostic value and the other for PCR with P1 and P4 to amplify the standard form of CD44, with or without all splice variants, as an internal control.

Thirty-five cycles PCR were then carried out. The cycle conditions were: 95°C 1 minutes, 55°C 1 minute, 72°C 2 minutes. A 'hot start' procedure was adopted for all samples. Results are shown in Figure 8.

Equal volumes of PCR products were loaded in each lane of a 1.2% agarose gel and stained with ethidium bromide. If the cells in the urine were to be expressing all the Exons from Exon 6 to Exon 14, it was predicted that with the current PCR protocol, using primers E1 and E4, should produce a 735 bp band. There is no band in tracks containing cDNA from normal urine or that of patients with non-neoplastic cystitis (lanes 1-8) but a clear 735 band is seen in all urine samples from patients with bladder cancer (lanes 9-16) when PCR was performed with primer E1 and E5 (upper panel).

A 482 bp band representing the standard form of CD44 was obtained almost equally in all cases when PCR was performed with P1 and P4 (lower panels). This indicates that the diagnostically significant differences between urine from patients with bladder

- 28 -

cancer and that from controls were not caused by unequal loading of the tracks but by alternative splicing of the CD44 gene. Lanes 1-4: normal urine. Lanes 5-8: cystitis urine. Lanes 9-16: from patients 1-8 with bladder cancer.

In the overall results this 735 bp band was completely absent in 7 of 7 normal and 9 of 9 cystitis-affected urine specimens; that is 0% false positive. Also 14 of 19 (74%) urine samples from patients with bladder cancer showed a positive result (i.e. 26% false negatives). In the false negative samples there was a shortage of viable cancer cells as indicated by fluorescein-d acetate ethidium bromide staining.

15

EXAMPLE 6

Stools from 12 patients were assayed by the techniques described herein. Of the samples from 9 patients with colorectal carcinoma, 5 gave positive results. Of the samples from 3 normal patients, all 3 gave negative results. These figures, obtained from samples full of bacteria which were not subjected to any pretreatment, encourage the belief that a viable diagnostic assay could be developed without difficulty.

In the inventors' further experience of detecting tumour cells with this method, the following observations would be useful to others investigating its diagnostic potential. The major considerations to be aware of are that the reliability and reproducibility of the results depend critically on the quality of the mRNA obtained from the sample and upon the care with which the techniques are performed. The main requirement is to eliminate false negative results by ensuring that high quality mRNA is routinely obtained and by using internal standards in every reaction to monitor the PCR amplification step. False positives, providing they are not too frequent, are not

a serious problem, because they can be recognised by replicate assays on the same or further samples and by reference to other clinical data.

The inventors have explored the procedures
5 needed to ensure the routine RT-PCR detection of
abnormal CD44 gene activity in small clinical samples
containing tumour cells. If a tissue sample is divided
into aliquots, half of which are frozen in liquid
nitrogen immediately and the remainder of which are
10 left at ambient temperature, one can show how the
ability to detect CD44 splice variants declines with
time and with mode of specimen handling. Fresh samples
submitted to mRNA extraction within half an hour of
excision give the most reliable results and there is a
15 gradual decline in quality over the next few hours if
the fresh tissue is left at ambient temperature. If
the sample is first snap frozen, the results obtained
when RNA is extracted immediately after thawing are
satisfactory, but decline very rapidly, beginning
20 within 15 minutes, the larger variant transcripts being
lost first and ultimately even the standard form. It
is also found that if snap-frozen cell and tissue
samples are stored at -70°C the results decline after 4
weeks, even if the mRNA is extracted immediately after
25 thawing. It would seem therefore that degradation of
RNA by ribonucleases released from cells ruptured
during freezing continues, even at this temperature,
although at slower rates. Further, as one would
expect, if the sample taken for RNA extraction is from
30 an area of necrosis or of fibrosis, one does not obtain
the typical results seen with viable tumour tissue.
Hence, care in sample selection and in specimen
processing are both needed for generating reliable
data.

35 Arising out of this, we prefer that a fresh
sample should be held for not more than 24 hrs before

- 30 -

being either frozen or treated to extract mRNA; and that a thawed sample should be held for not more than 2 hrs before being treated to extract mRNA.

The diagnosis method described herein can be performed in a single day, possibly in a few hours, and is capable of being automated. Use of the method has been demonstrated, on various tissue samples to detect a whole variety of cancers, and also on blood and urine samples. We therefore offer it as a convenient practical method for cancer screening and diagnosis. In principle it could also have wide general applicability to cancer detection and prevention programmes and therefore have epidemiologic and public health value. Proper application of its sensitivity, specificity and simplicity should add not only to initial cancer diagnosis but to evaluation of extent of disease in the body, to judgment of the efficacy of treatment and to early detection of tumour recurrences.

20 FIGURE LEGENDS:

Notation: N = normal, T = primary tumour,
M = metastasis.

Figure 1

25 Autoradiogram of PCR products from breast tissue samples probed with E4 (10 hours exposure of X-ray film to sample filter). Panel A: malignant primary breast carcinomas with their metastases. Tracks 1, 2 and 3: patient B1; tracks 4, 5 and 6: patient B2; tracks 7, 8 and 9: patient B3; tracks 10 and 11: patient B4; tracks 12 and 13: patient B5. It can be seen that compared to normal breast tissue, primary breast carcinomas and their metastatic deposits overexpress several splice-variants. Note the doublet (arrows) at 1500bp and 1650bp best seen in track 5. This is present in all tumours and metastases but is

- 31 -

fogged in the other tracks by this time of exposure. It is not detectable in any normal samples even at much longer exposure times (23 hours). Panel B: Breast carcinomas with no clinical evidence of metastasis.

- 5 Tracks 14-20 are from patients B15-B21. The tumours all overexpress several variants, but show less bands and the signal intensity is less, except track 16 (patient B17) - see text. The 1500/1650bp doublet (arrow) is easily recognisable in tracks 15, 16 and 18
10 at this length of exposure and became detectable in all other tumour-containing tracks on longer exposure. The illustration, however, shows only the shorter exposure, to avoid fogging the tracks which have stronger signals. Panel C: Fibroadenomas (FA) and fibrocystic
15 disease of the breast (Cyst). Tracks 21 and 22, containing the benign tumour samples (samples B22 and 23), express more than the non-neoplastic sample (fibrocystic disease) in track 23 (sample B24).

20 Figure 2

- Autoradiogram of PCR products from breast tissue samples probed with probe P2 (1.5 hours exposure of X-ray film to sample filter). This result was obtained by reprobing the same filter as that used in
25 Figure 1, after stripping off the previous probe. Here it can be seen that i) the differences observed in Figure 1 are not due to unequal loading of tracks, ii) that the expression of the standard form of the molecule is quantitatively greater than any of the
30 variants, iii) the standard form is expressed in all tissues examined and iv) further variants which do not contain exon 3 transcripts, are also present and over-expressed in tumours. The 1500/1650bp doublet can be recognised in the tumours in panel A but needed
35 longer exposure to be detectable in panels B and C.

- 32 -

Figure 3

Autoradiogram of PCR products from colon tissue samples probed with E4 (10 hours exposure of photographic film to sample filter). Tracks 1, 2 and 3: patient C1; tracks 4, 5 and 6: patient C2; tracks 7, 8 and 9: patient C3; tracks 10 and 11: patient C4; tracks 12 and 13: patient C5; track 14: normal liver sample. The picture shows the same features as described in the legend to Figure 1 and that the findings apply to carcinomas of the colon. The 1500/1650bp doublet (arrow) is easily recognisable in several tumour tracks (2 and 8-12) and the faint signal in the corresponding position in tracks 3, 5, 6 and 13 became stronger on longer exposure. However none appeared in this vicinity in tracks 1, 4, 7 or 14 (normal tissue).

Figure 4

Autoradiogram of PCR products from colon tissue samples probed with P2 (1.5 hours exposure of photographic film to sample filter). This confirms equal loading of the tracks and that other points, illustrated in Figure 2, apply to colon carcinomas. Note that normal liver expresses the standard form of CD44.

Figure 5

Autoradiogram of PCR products of normal peripheral blood leukocytes, PBL (from 3 different persons) and other normal tissues probed with E4 (panel A; 8 hours exposure to photographic film) and P2 (panel B; 5 hours exposure to photographic film). Track 6 contains PCR products from a breast cancer (patient B1) as a positive control. With this combination of primers and probes, leukocytes can be seen to express the standard form of the CD44 molecule, but no

- 33 -

detectable splice variants. The samples in tracks 4 and 5 were from individuals with no clinical evidence of neoplasia, as follows: track 4, breast tissue obtained at autopsy from the body of a woman who died
5 of bacterial endocarditis; track 5, colon resected for volvulus.

10

15

20

25

30

35

- 34 -

TABLE 1

PATIENT	AGE	DISEASE	TUMOUR SIZE	METASTASIS	HISTOLOGY (GRADE)	CLINICAL STAGE
B1	56	Breast ca	2.5cm	Lymph node		
B2	53	Breast ca	3cm	Lymph node		
B3	65	Breast ca	3cm	Lymph node		
B4	54	Breast ca	5cm	Lymph node (10/10)	IDC (mucinous)[1]	
B5	59	Breast ca	5.5cm	Lymph node		
B6	59	Breast ca	3cm	Lymph node		
B7	61	Breast ca	4cm	Lymph node (17/17)	ILC/IDC	3
B8	38	Breast ca	3.5cm	Lymph node (1/5)	ILC	2
B9	65	Breast ca	1.8cm	Lymph node (5/6)	ILC	2
B10	61	Breast ca		Lymph node (10/13)	IDC [1]	2
B11	80	Breast ca	11cm	Lymph node	3	
B12	65	Breast ca	2.3cm	Lymph node	?1	
B13	68	Breast ca	2.8cm	Lymph node (4/12)	IDC [3]	2
B14	47	Breast ca	7cm	Lymph node		2
B15	38	Breast ca		None (0/7)	IDC	1
B16	62	Breast ca	3cm	None (0/4)	IDC [3]	1
B17	62	Breast ca	3cm	None (0/16)	IDC [2]	1
B18	63	Breast ca	3cm	None (0/16)	1	
B19	61	Breast ca	3cm	None	1	
B20	42	Breast ca	4cm	None	IDC	1
B21	65	Breast ca		Lymph node	IDC/ILC	

SUBSTITUTE SHEET

PATIENT	AGE	DISEASE	TUMOUR SIZE	METASTASIS	HISTOLOGY (GRADE)	CLINICAL STAGE
B22	54	Breast ca	6cm	None (0/4)	IDC	1
B23	49	Fibroadenoma	4cm	-	-	-
B24	47	Fibroadenoma	3cm	-	-	-
B25	29	Cystic disease	-	-	-	-
C1	72	Colon ca	5.0cm	Lymph node	Well diff. adeno	3[C]
C2		Colon ca		Lymph node		
C3	65	Colon ca	6.5cm	Liver	Mod diff. adeno	4[D]
C4	56	Colon ca	7.8cm	Lymph node	Mod diff. adeno	4[D]
C5		Colon ca		Lymph node		
C6	57	Colon ca	5cm	Lymph node	Mod diff. adeno	3[C]
C7		Colon ca		None		
C8	75	Colon ca	6.5cm	Lymph node	Mod diff. adeno	3[C]
C9	72	Colon ca	5.5cm	Lymph node	Mod diff. adeno	3[C]
C10	76	Colon ca	4.5cm	None	Well diff. adeno	1[B]
T1		Thyroid ca				

Key:

IDC: infiltrating ductal carcinoma

ILC: infiltrating lobular carcinoma

Well diff. adeno: Well differentiated adenocarcinoma

Mod diff. adeno: Moderately differentiated adenocarcinoma

Letters in square brackets in Clinical Stage column refer to Dukes staging scheme for colon carcinoma

SUBSTITUTE SHEET

REFERENCES

1. Stamenkovic, Amiot M, Pesando J. M, Seed B.
A lymphocyte molecule implicated in lymph node homing
is a member of the cartilage link protein family. Cell
5 1989; 56: 1057-062.
2. Birch M, Mitchell S, Hart I.R. Isolation and
characterisation of human melanoma cell variants
expressing high and low levels of CD44. Cancer Res.
1991; 51: 6660-6667.
- 10 3. Gunthert U, Hofmann M, Rudy W, Reber S,
Zoller M, Haubmann, Matzku S, Wenzel A, Ponta H,
Herrlich P. A new variant of glycoprotein CD44 confers
metastatic potential to rat carcinoma cells. Cell
1991; 65: 13-24.
- 15 4. Sy M S, Guo Y-J, Stamenkovic I. Distinct
effects of two CD44 isoforms on tumor growth in vivo.
J. Exp. Med 1991; 174: 859-866.
5. Hofmann M, Rudy W, Zoller M, Tolg C, Ponta H,
Herrlich P, Gunthert U. CD44 splice variants confer
20 metastatic behaviour in rats: Homologous sequences are
expressed in human tumor cell lines. Cancer Res. 1991;
51: 5292-5297.
6. Stamenkovic I, Aruffo A, Amiot M, Seed B.
The hematopoietic and epithelial forms of CD44 are
25 distinct polypeptides with different adhesion
potentials for hyaluronate-bearing cells. EMBO J.
1991; 10: 343-348.
7. Jackson D. G, Buckley J, Bell J. I. Multiple
variants of the human lymphocyte homing receptor CD44
30 generated by insertions at a single site in the
extracellular domain. J. Biol. Chem. 1992; 267:
4732-4739.
8. Chomzynski P, Sacchi N. Single-step method
of RNA isolation by acid guanidinium thiocyanat-
35 phenol-chloroform extraction. Anal Biochem. 1987;
162: 156.

- 37 -

9. Knudson A. G. Hereditary cancer, oncogenes and antioncogenes. Cancer Res. 1985; 45: 1437-43.
10. Tarin D. Tumour metastasis. In: Oxford Textbook of Pathology 1992; (eds: J O'DMcGee, N. A. Wright, P. G. Isaacson). Oxford University Press, Oxford. pp607-633.
11. Hayle A. J, Darling D. L, Taylor A. R, Tarin D. Transfection of metastatic capability with total genomic DNA from metastatic tumour cell lines. Differentiation, 1993, in press.
12. Screatton G. R., Bell M. V., Jackson D. G., Cornelis F. B., Gerth U., and Bell J. I., Genomic Structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons, Proc. Natl. Acad. Sci. USA, Vol 889, p 12160-4, December 1992, Immunology.

20

25

30

35

EXAMPLE 7:

I. Peptide Synthesis

5 peptides corresponding to amino acids 1-13, 9-23, 19-33, 29-43 and 1-43 of the peptide sequence corresponding to CD44 exon 6 as shown in Figure 7 were synthesized by 9-fluorenylmethyloxycarbonyl (Fmoc) chemistry solid phase peptid synthesis (Atherton and Sheppard, 1989) on an Applied Biosystems, Inc., Model 431A Peptid Synthesizer using the proprietor's standard scale (0.25 mmol) Fmoc chemistry option. For this purpose, 403 mg 4-(2', 4'-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxy resin (Rink, 1987) with a substitution of 0.62 mmol/g resin are used. The amide resin is deprotected (Fmoc cleavage) by treatment with 20% piperidine in N,N-dimethyl formamide (DMF) before the first coupling cycle. For peptide synthesis, a 4-molar excess of the following Fmoc-amino acid derivatives and other carboxylic acids is used:

- N-Fmoc-L-alanine
- 20 N- α -Fmoc-N^G-(2,2,5,7,8-pentamethylchroman-6-sulfonyl)-L-arginine
- N- α -Fmoc-N- β -(trityl)-L-asparagine
- N- α -Fmoc-L-aspartic acid- β -t-butyl ester
- N-Fmoc-S-trityl-L-cystein
- 25 N- α -Fmoc-N-gamma-(trityl)-L-glutamine
- N- α -Fmoc-L-glutamic acid-gamma-t-butyl ester
- N- α -Fmoc-N-im-trityl-L-histidine
- N-Fmoc-L-leucine
- N- α -butyloxycarbonyl-N- ϵ -Fmoc-L-lysine
- 30 N- α -Fmoc-N- ϵ -butyloxycarbonyl-L-lysine
- N-Fmoc-L-norleucine
- N-Fmoc-L-phenylalanine
- N-Fmoc-L-proline
- N-Fmoc-O-t-butyl-L-serine
- 35 N-Fmoc-O-t-butyl-L-threonine
- N- α -FMoc-N- ϵ -butyloxycarbonyl-L-tryptophan

- 39 -

N-Fmoc-gamma-aminobutyric acid

N-Fmoc-ε-aminocaproic acid

(+) -Biotin

5 Prior to coupling, the amino acid derivatives
are dissolved in DMF and activated through the addition
of 1 equivalent N-hydroxybenzotriazole (HOBt) in N-
methylpyrrolidinone (NMP) and 1 equivalent N,N'-
dicyclocarbodiimide (DCC) in NMP. The 20-minute
10 couplings of the HOBt-ester amino acid are carried out
in DMF. Following coupling, deprotection of the N-
termini (Fmoc cleavage) is achieved by a 3-minute and
then a 10-minute treatment with 20% piperidine in DMF.
The peptide chain is extended through repetition of the
15 activation/coupling/deprotection cycles. Peptides
utilized later for immunogen synthesis are outfitted
with an N-terminal aminocaproic acid spacer and
cystein, through which the peptide is tethered to the
carrier protein. For peptides used as screening
20 reagents, a different N-terminus is synthesized and
contains three gamma-aminobutyric acid moieties,
lysine, and biotin (attached to the ε-amino group of
lysine). Following synthesis, the peptide is removed
from the resin support by trifluoroacetic acid (TFA)
25 cleavage. The peptide-bearing resin is reacted for 1
hour at room temperature (RT) with a cleavage cocktail
containing 20 mL trifluoroacetic acid, 1 mL H₂O, 1 mL
thioanisole, 0.5 mL ethanedithiol and 1.5 g phenol.
Removal of the acid-labile side-chain protecting
30 groups, performed under Argon, is complete after an
additional 2.4 h reaction time at RT in the
aforementioned cocktail solution. After a brief
cooling period, the deprotected peptide is precipitated
through the addition of diisopropylether. The
35 precipitate is filtered, washed with diisopropylether,
dissolved in 50% acetic acid, frozen and lyophilized.

SUBSTITUTE SHEET

Peptide purity is determined by reverse-phase HPLC (column - Vydac 218TP54, C₁₈, 300 Å, 5 µm, 4.6 x 250 mm; mobile phase - A: 0.1% TFA in H₂O, B: 0.1% TFA in H₂O/acetonitrile (35/65, v/v); gradient - 0-100% B in 90 min; flow rate - 1 mL/min; detection - 226 nm). Those peptides being less than 60% pure are purified by reverse-phase HPLC (column - Waters DeltaPak C₁₈, 100 Å, 15 µm, 50x300 mm; mobile phase - A: 0.1% TFA in H₂O, B: 0.1% TFA in H₂O/acetonitrile 35/65, v/v, gradient - 0.50% B in 130 min; flow rate - 15 mL/min; detection - 226 nm). Peptide identity is verified by plasma desorption mass spectrometry. Characteristic HPLC retention times and mass spectral data for the peptides used for immunogen synthesis are listed in Table 2.

Table 2 HPLC and MS Characteristics of Activated Hapten Peptides

Peptid Name	Sequence ¹	Theoret. mass	Exp. mass (MH ⁺)	Exp. Theoret	Retention time (min) ²
AH, CD44(AT1-13NH ₂ , 1-ZC)	H-CZATTLJSTSATAT ETA-NH ₂	1651.76	1653.3	+1.54	36.01
AH, CD44(9-23NH ₂ , 9-ZC)	H-CZATETATKROETW DWF-NH ₂	2155.31	2155.8	+0.49	45.29
AH, CD44(19-33NH ₂ , 19-ZC)	H-CZTWDWFSWFLPS ESK-NH ₂	2214.47	2215.7	+1.23	61.73
AH, CD44(29-43NH ₂ , 29-ZC)	H-CZPSESKNHLHTTT QJA-NH ₂	1950.15	1950.5	+0.35	28.92
AH, CD44(1-43NH ₂ , 1-ZC)	H-CZTLJSTSATATETA KROETWDWFSWFLP SESKNHLHTTTOJA-NH ₂	5150.5	5149	-1.50	57.64

¹ J=norleucine, Z= aminocaproic acid, other abbreviations from standardized one-letter code

² Retention times obtained using aforementioned HPLC conditions.

II. Activation of Carrier Protein

For immunogen synthesis, a carrier protein, either Keyhole Limpet Hemocyanin (KLH) or Bovine Serum Albumin (BSA), is modified through the ϵ -amine of lysines with the heterobifunctional cross-linking reagent, N-succinimidyl 3-maleimidopropionate (MPS). This imparts the carrier protein with "handles" onto which the sulfhydryl peptides are later conjugated. For the case of KLH, a 10 μ M KLH solution is prepared with 0.1 M NaHCO_3 , pH 8.35. The pH of the suspension is adjusted to 8.3 and briefly centrifuged. After determining the protein concentration by the bicinchoninic acid (BCA) protein assay (Smith, et al., 1985), 3000 equivalents of a 0.3 M MPS solution in dimethylsulfoxide are added dropwise to the stirred KLH solution and allowed to react at RT for 1 hour. The solution pH is adjusted to 7.0 with 0.1 M HCl, and activated carrier protein is separated from excess MPS by size-exclusion chromatography (column - Aca 202, IBF Biotechnics, 5x12 cm, RT; buffer - 0.1 M $\text{KH}_2\text{PO}_4/\text{K}_2\text{HPO}_4$ pH 7.0, 0.1 M NaCl; flow rate - 6 mL/min, detection - 226 nm). Protein concentration is again determined by the BCA Protein assay and the degree of maleimido-propionamide (MP) substitution of the activated KLH (KLH-MP) is determined with the Ellman's reagent, DTNB (Ellman, 1959). For BSA, a 190 μ M BSA solution is prepared in 0.1 M $\text{KH}_2\text{PO}_4/\text{K}_2\text{HPO}_4$ pH 7.0, to which is added dropwise 100 equivalents MPS (40 mM in 1,4-dioxane). After stirring the reaction mixture for 2 hours at RT, it is loaded onto a size-exclusion column. The activated BSA (BSA-MP) is purified and analysed analogous to KLH-MP). Substitution values of 20-35:1 and 200-600:1 are routinely achieved for the activated carrier proteins, BSA-MP and KLH-MP, respectively.

SUBSTITUTE SHEET

III. Conjugation of Peptide with Activated Carrier Protein.

Through formation of a thioether bond, thiol-containing peptides are conjugated with the MP-activated carrier protein. In the case of BSA-MP, a 74 μ M BSA-Mp solution in 0.1 M $\text{KH}_2\text{PO}_4/\text{K}_2\text{HPO}_4$ pH 7.0 is reacted with 1 equivalent (with respect to MP) of a 4 mM peptid solution in the same phosphate buffer. The solution is stirred slowly and allowed to react at RT overnight. After centrifugation, the soluble BSA-MP-peptide conjugate is separated from unbound peptide via size-exclusion chromatography (same chromatography conditions as given in section II). Analyses of the protein conjugate include protein concentration determination via BCA, as well as ascertaining the remaining number of unreacted MP-groups with Ellman's reagent. KLH-MP-peptide conjugates are synthesized similarly with the exception of activated carrier protein and peptide concentrations, which are 3 μ M and 18 μ M, respectively.

REFERENCES

- Atherton, E. and Sheppard, R.C. (1989) Solid Phase Peptide Synthesis: A Practical Approach, Oxford, U.P., Oxford.
- Ellman, G.L. (1959) Arch. Biochem. Biophys. 82, 70-77.
- Rink, H. (1987) Solid-Phase Synthesis of Protected Peptide Fragments Using a Trialkoxydiphenylmethylester Resin. Tetrahedron Letters 28, 3787-3790.
- Smith P.K., Krohn, R.I., Hermanson, G.T., Mallia, A.K., Gartner, F.H., Provenzano, M.D., Fujimoto, E.K., Goeke, N.M., Olson, B.J. and Klenk, D.C. (1985) Measurement of Protein Using Bicinchoninic Acid Anal. Biochem. 150, 76-85.

ABBREVIATIONS

	BCA - bicinehoninic acid
	BSA - bovine serum albumin
	BSA-MP - bovine serum albumin activated with
5	N-succinimidyl 3-maleimidopropionate
	DCC - N,N'-dicyclocarbodiimide
	DMF - N,N-dimethylformamide
	DTNB - dithio-bis-(2-nitrobenzoic acid),
	Ellman's reagent
10	Fmoc - 9-fluorenylmethyloxycarbonyl
	HOBt - N-hydroxybenzotriazole
	KLH - Keyhole Limpet hemocyanin
	KLH-MP - Keyhole Limpet hemocyanin activated
	with N-succinimidyl 3-maleimidopropionate
15	MP - maleimidopropionamide
	MPS - N-succinimidyl 3-maleimidopropionate
	NMP - N-methylpyrrolidinone
	RT - room temperature
	TFA - trifluoroacetic acid
20	
25	
30	
35	

- 43 -

EXAMPLE 8:

Manufacture of the recombinant HIV2 (gp32)-CD44 exon 6 antigen/immunogen

5 Exon 6 of the CD44 gene codes for a peptide of 43 amino acids as shown in Figure 7.

 Peptides and small proteins of less than 100 amino acids as a rule cannot be made recombinantly by cytoplasmic expression in a microorganism. For this
10 reason, a fusion gene comprising a gene which is readily expressible in E. coli (part of the envelope protein gp32 of the HIV2 retrovirus) and CD44 exon 6-DNA was constructed.

 To increase the CD44 exon 6 epitopes in the
15 fusion protein, the CD44 exon 6 antigen was duplicated at the DNA level using a suitable linker (codes for the 3 C-terminal amino acids of the exon 5 of CD44):

 Six histidine residues (codons) were inserted in the N-terminal region of the HIV2 (gp32)-CD44 exon 6
20 fusion protein at the DNA level for the purpose of simpler antigen/immunogen isolation by means of metal chelate affinity chromatography.

Recombinant DNA Technique

25 Standard methods were used to manipulate the DNA such as those described by Sambrook, J. et al. (1989) In: Molecular cloning: A laboratory manual. Cold Spring Harbor Press, Cold Spring Harbor, New York. The molecular biological reagents were used according
30 to the manufacturer's instructions.

Construction of HIV2 (gp32)-partial gene (plasmid pUC18_HIV2-gp32)

35 The coding section of the amino acid 48-162 of the HIV2-gp32 gene was synthesized by overlapping chemical gene synthesis and subsequently subcloned in

the plasmid pUC18. Production and description of the plasmid pUC18_HIV2-gp32 are described in the European Patent Application 0 440 207.

5 Construction of the E.coli expression vector
pDS56-6HIS-HIV2-gp32

In the following plasmid construction, a fusion gene was constructed which codes for the N-terminal of the amino acid sequence MRGSHHHHHHTDPEF
10 (poly-His tail) and the selected HIV2-g[32 antigen.

For this purpose, the vector pQE-10 was digested with restriction endonucleases BamHI and HindIII, and the approx. 3.4-kbp-long BamHI/HindIII-pQE-10 vector fragment isolated by
15 agarose gel electrophoresis. The pQE-10 vector [synonym: pDS56/RBSII, 6xHis(-1)] is sourced from Diagen, Germany, and is described in Stuber, D. et al. (1990) Immunol. Methods IV: 121-152. In a second preparation, the plasmid pUC18_HIV2-gp32 was digested
20 by the restriction endonucleases BamHI and HindIII, and the ca. 400-bp-long BamHI/HindIII-HIV2-gp32 fragment isolated and ligated into the approx. 3.4-bp-long BamHI/HindIII-pQE-10 vector fragment. The desired plasmid was identified by restriction mapping and
25 designated pDS56-6HIS-HIV2-gp32.

Construction of E.coli expression vector pDS56-HIV2-
CD44 exon 6

In the following plasmid construction, a
30 fusion gene was constructed which codes N-terminal for the amino acid sequence MRGSHHHHHHTDPEF (poly-His tail), the selected HIV2-gp 32 antigen, and 2 copies of the CD44 exon 6 antigen.

Two copies of the CD44 exon 6 gene were
35 produced by polymerase chain reaction (PCR) [Mullis, K.B. and Faloona, F.A. (1987) Methods Enzymol. 155:

335-350] .

In a first PCR reaction, the CD44 exon 5-6 DNA sequence from base pair position 397-538 was amplified (see Fig. 9: DNA sequence of HIV2(gp32)-CD44 exon 6 fusion gene) and provided with suitable singular restriction endonuclease cleavage sites (BamHI and HaeIII). Subcloned CD44 cDNA (Exon 5-11) and the following primer pair were used for amplification:

10

Primer (1) : 5'-aaaaaaCGATCCccggctaccacttttgatgagcactagtgtctac-3'
ProAlaThrThrLeuMetSerThrSerAla...
Exon 5 Exon 6

15

Primer (2): 5'-aaaaaaGGCCGGagccatttgtgttgttgtgtg-3'

The approx. 160-bp-long PCR product was digested with BamHI and HaeIII and the approx. 150-bp-long BamHI/HaeIII-CD44 exon 6 fragment isolated by agarose gel electrophoresis.

25 In a second PCR reaction, the CD44 exon 5-6 DNA sequence of base pair position 539-672 (see Fig. 9: DNA sequence of HIV2(gp32)-CD44 exon 6 fusion gene) was amplified and provided with suitable singular restriction endonuclease cleavage sites (HaeIII and HindIII) using subcloned CD44 cDNA exon 5-11 as template DNA and the following primer pair:

30

HaeIII
 Primer (3): 5'-aaaaaaCCGCCCACTttgatgagcactagtgcctac-3'
 ProAlaThrThrLeuMetSerThrSerAla..
 Exon 5 Exon 6

35

Primer (4): 5'-aaaaaaaAAGCTTTATCAagccatttgtgttgttggtg-3'

The approx. 150-bp-long PCR product was digested by HaeIII and HindIII and the approx. 140-bp-long BamHI/HaeIII-CD44 (Exon 6) fragment isolated by agarose gel electrophoresis.

- 5 Then the BamHI/HaeIII-CD44 exon 6 fragment from the first PCR reaction and the HaeIII/HindIII-CD44 exon 6 from the 2nd PCR reaction were ligated by 3-fragment ligation into an approx. 3.8-bp-long BgIII/HindIII-pDS56-6HIS-HIV2-gp32 vector fragment.
- 10 The desired plasmid was identified by restriction mapping and the PCR-synthesised DNA regions checked by DNA sequencing (construction: pDS56-HIV2-CD44 exon 6).

15 Expression of the HIV2(gp32)-CD44 exon 6 antigen in E.coli

- To express the HIV2(gp32)-CD44 exon 6 antigen in E.coli, the E.coli K12 strain RM82 (a methionine revertant of EX8654, Murry, N.E. et al. (1977) Mol. Gen. Genet. 150: 53-61) was transformed with the
- 20 HIV2(gp32)-CD44 exon 6 expression plasmid pDS56-HIV2-CD44 exon 6 (resistance ampicillin) and the IacI repressor plasmid pUHA1 (resistance kanamycin). Production and description of the plasmid pUHA1 are described in Stuber, D. et al. (1990)

25 45

Immunol. Methods IV: 121-152.

- RM82/pUHA1/pDS56-HIV2-CD44 exon 6 cells were cultured in DYT medium (1% (w/v) yeast extract, 1%
- 30 (w/v) Bacto Tryptone, Difco, and 0.5% NaCl) with 50 mg/l ampicillin and 50 mg/l kanamycin up to an optical density of 0.6-0.9 at 550 nm, and then induced with IPTG (1-5 mmol/l end concentration). After an induction phase of 4-8 h, the cells were harvested by
- 35 centrifugation, washed with 10 mmol/l phosphate buffer, pH 6.8, and stored at -20°C until further processing.

- 47 -

The cell pellet from 1 ml of culture medium (RM82/pUHA2/pDS56-HIV2-CD44 exon 6 cells) was re-suspended in 0.25 ml 10 mmol/l phosphate buffer, pH 6.8, and 1 mmol/l EDTA and the cells mechanically lysed
5 by means of a French press. After centrifugation, 1/5 volumes of 5xSDS sample buffer: 50 mmol/l Tris-HCl, pH 6.8, 1% SDS, 1% mercaptoethanol, 10% glycerol, and 0.001% bromophenol blue) was added to the supernatant. The insoluble cell debris fraction was resuspended in
10 0.3 ml 1xSDS sample buffer with 6-8 M urea. The samples were then incubated for 5 min at 95°C and centrifuged. Thereafter, the proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE) (Laemmli, U.K. (1970) Nature 227: 680-685) and stained
15 with Coomassie Brilliant Blue R dye.

The HIV(gp32)-CD44 exon 6 antigen (Figure 10) synthesized in E.coli was homogeneous and found exclusively in the insoluble cell fraction. The expression level for the HIV2(gp32)-CD44 exon 6 antigen
20 was 30-50% in relation to the E.coli total protein.

Preparation of HIV2(gp32)-CD44 exon 6 antigen from E.coli

Cell lysis and preparation of inclusion
25 bodies (IB's).

20 g (wet weight) of RM82/pUHA1/pDS56-HIV2-CD44 exon 6 cells were re-suspended in 100 ml 0.1 mol/l Tris-HCl, pH 7.0, at 0°C. 30 mg lysozyme was added, and the mixture was incubated for 20 min at 0°C. The
30 cells were then lysed completely by mechanical high pressure dispersion, and the DNA was digested in 30 min at 25°C by addition of 2 mmol/l MgCl₂ and 1 mg DNAase (Boehringer Mannheim, Germany, Cat. No. 154709). Then 50 ml 60 mmol/l EDTA, 6% Triton X100 and 1.5 mmol/l
35 NaCl, pH 7.0, were added to the digested solution and this mixture incubated for a further 30 min at 0°C.

- 48 -

The insoluble components (cell debris and IB's) were then centrifuged down on a Sorvall centrifuge. The pellet was resuspended in 100 ml 0.1 mol/l phosphate buffer, pH 8.5, incubated for 30 min at 25°C, and the
5 IB product isolated by centrifugation.

Purification of the HIV2(gp32)-CD44 exon 6 antigen using metal chelate chromatography

The 2.5 g IB pellet (wet weight) was
10 suspended in 25 ml 6 mol/l guanidine-HCl, 0.1 mol/l phosphate buffer, pH 8.5, by stirring for 2 h at 25°C. The insoluble components were separated off by centrifugation and the clear supernatant applied to an NTA column equilibrated with 6 mol/l guanidine-HCl, 0.1
15 mol/l phosphate buffer, pH 8.5 (column volume: 50 ml, NTA gel from the Diagen Company, Germany; Hochuli, E. et al. (1988). Bio/Technology 6: 1321-1325).

The column was then washed with about 5 column volumes of 8 mol/l urea, 10 mmol/l Tris-HCl, and
20 0.1 mmol/l phosphate buffer, pH 8.5. Subsequently, the HIV2(gp32)-CD44 exon 6 antigen was eluted with 8 mol/l urea and 0.1 mol/l phosphate buffer, pH 4.0, and the HIV2(gp32)-CD44 exon 6 antigen-containing fractions pooled.

25

Expression and isolation of the HIV2 (gp32)-carrier antigen in E. coli

Analogous to the HIV2 (gp32)-CD44 exon 6 antigen the HIV2 (gp32) carrier antigen was produced by
30 using the plasmid pDS56-6HIS-HIV2-gp32.

Biotinylation of HIV2 (gp32)-CD44 exon 6 antigen

Biotinylation was performed with biotinoyl--aminocaproic acid-N-hydroxy-succinimide (Bi-X-NHS)
35 (Boehringer Mannheim, Germany Cat. No. 1003933) in the molar ratios 1:3, 1:6, and 1:10. The fusion protein

- 49 -

HIV2 (gp32)-CD44 exon 6 present in a concentration of 7.1 mg/ml in 8 M urea, 0.1 M sodium phosphate buffer, 10 mM Tris, pH ca. 6, was diluted with dialysis buffer (0.1 M sodium phosphate buffer, 0.5% SDS, 10 mM DTT, pH 8.5) to 2 mg/ml and dialyzed against the aforementioned dialysis buffer at room temperature and further diluted to 1 mg/ml. The appropriate quantity of Bi-X-NHS was added to the fusion protein, incubated for 2 h at room temperature, and then the reaction was stopped by addition of 1 M lysine/HCl, pH 6.5, to 2 mM. After dialysis against 0.1 M sodium phosphate buffer, 0.5% SDS, pH 6.0, the reagent HIV2 (gp32)-CD44 exon 6-Bi was stored at -20°C.

The peptide HIV2 (gp32) was biotinylated analogous.

References

- Hochuli, E.; W. Bannwarth; H. Dbeli; R. Genz; D. Stuber (1988). Genetic approach to facilitate purification of recombinant proteins with a novel metal chelate adsorbent. *Bio/Technology* 6: 1321-1325
- Laemmli, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227: 680-685
- Mullis, K.B.; F.A. Faloona (1987). Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. *Methods Enzymol.* 155: 355-350
- Murray, N.E.; W.J. Brammar, K. Murray (1977). Lambdoid phages that simplify the recovery of in vitro recombinants. *Mol. Gen. Genet.* 150: 53-61.
- Sambrook, J.; E.F. Fritsch, T. Maniatis (1989). *Molecular cloning: A laboratory manual*. Cold Spring Harbor Press, Cold Spring Harbor, New York
- Screaton, G.R.; M. Bell, D.G. Jackson, F.B. Cornelis, U. Gerth, J.I. Bell (1992). Genomic structure of DNA encoding the lymphocyte homing receptor CD44

reveals at least alternatively spliced exons. Proc. Natl. Acad. Sci. 89: 12160-12164

Stuber, D.; H. Matile, G. Garotta (1990).
System for high level production in Escherichia coli
5 and rapid application to epitope mapping, preparation
of antibodies, and structure-function analysis.
Immunol. Methods IV: 121-152

EXAMPLE 9

10 Immunization of mice

Immunization of mice was performed according
to Cianfriglia et al. (1983). Hybridoma, Vol. 2, No. 4:
451-457. As immunogen synthetic peptides corresponding
to amino acid 1 - 13, 9 - 23, 19 - 33, 29 - 43 and 1 -
15 43 coupled to a carrier protein (see example 7) as well
as the HIV2 (gp32)-CD44 exon 6 antigen were used.

12-week old Balb/c mice were immunized with
50 µg immunogen in complete Freund's adjuvant
intraperitoneally 15 and 8 days prior to fusion. 3 days
20 before fusion, they were immunized intraperitoneally
with 200 µg immunogen in PBS buffer, and 2 days before
fusion and on the last day before infusion they were
immunized both intraperitoneally and intravenously with
100 µg immunogen in PBS buffer.

25

Fusion and cloning

Manufacture of spleen cell suspension

Mice were terminated by cervical dislocation,
and their spleens removed under sterile conditions. The
30 spleen cells were teased out of the connective tissue
in RPMI 1640 basic medium. The cell suspension was then
passed through a sieve and centrifuged at 200 g
(centrifuge tubes) in RPMI basic medium.

35 Fusion

Spleen cells from an immunized mouse were

mixed in a ratio 1 + 5 with P3x63Ag8- 653 myeloma cells (ATCC CRL 8375) and centrifuged (10 min, 300 g, 4°C). The cells were washed again with RPMI basic medium and centrifuged at 400 g. The supernatant was decanted off and then 1 ml PEG (Mr 4000, Merck) was added and mixed by pipetting. After 1 min on a water bath, 5 ml RPMI 1640 basic medium was added drop-wise at room temperature over a period of 5-6 min and the mixture made up to 50 ml with medium (RPMI 1640 + 10% FCS). Subsequently this was centrifuged for 10 min at 400g, 4°C. The sedimented cells were added to RPMI 1640 medium + 10% FCS and seeded in 96-well culture plates at 2.5×10^4 spleen cells per well in 200 µl selection medium (100 µM hypoxanthin, 1 µg/ml azaserin in RPMI 1640 + 10% FCS) [FCS = fetal calf serum].

After 10 days, these primary cultures were tested for specific antibody synthesis. Primary cultures of appropriate specificity were cloned in 96-well culture plates using an FACS (cell sorter). As growth factor, Interleukin 6 (Boehringer Mannheim Cat. No. 1271172, 100 U/ml) was added to the medium.

In this way, the following hybridoma cell lines were isolated; they have been deposited at the DMS facility in Braunschweig:

MAK<CD44>M-1.1.12
MAK<CD44>M-2.42.3
MAK<CD44>M-4.3.16

For MAK<CD44>M-1.1.12 a synthetic peptide corresponding to amino acids 9 - 23, for MAK<CD44>M-2.42.3 a synthetic peptide corresponding to amino acids 29 - 43 and for MAK<CD44>M-4.3.16 a synthetic peptide corresponding to amino acids 1 - 13 of the CD44 exon 6 peptide having the amino acid sequence shown in Figure 7 was used.

Antibody production

Obtaining antibodies from ascites

5 5×10^6 hybrid cells were injected i.p. into two mice pre-treated with 0.5 ml Pristan. After 1-3 weeks, ascites with an IgG concentration of 5-20 mg/ml was obtained. From this antibodies were isolated in the usual manner.

Obtaining antibodies from cell culture supernatants

10 Hybridoma cells were multiplied over a period of 7 days at an inoculation density of 1×10^5 cells/ml in RPMI 1640 +10% FCS on a Techne biological stirrer (THERMO- DUX, Wertheim/Main, Model MCS-104XL, Cat. No. 144-050). Mean concentrations of 100 μ g MAB/ml were
15 achieved in the culture supernatant. Purification was performed using standard protein chemistry methods.

EXAMPLE 10

Assessment of the specificity of the produced 20 antibodies

Antibodies to synthetic CD44 peptide

To establish antibody specificity in the hybridoma cell-culture supernatant, reactivity towards the partial peptide sequence and the entire exon 6 was
25 determined in parallel by inhibition test. 96-well titer plates (Nunc) were coated with 200 μ l/well of streptavidin [10 μ g/ml, coating buffer = 0.2 mol/l sodium carbonate/bicarbonate]. After coating with streptavidin, the biotinylated peptide e.g. 1-13
30 biotin, 9-23 biotin, 19-33 biotin, 29-43 biotin, c = 2.5 μ g/ml was bound in incubation buffer [sodium phosphate buffer, 40 mM, 0.5% Crotein C, 100 μ l/well, incubation 1 h, room temperature]. The free binding sites were saturated with blocking buffer [0.9% NaCl, 1% Crotein C, 200 μ l, 30 min, room temperature].
35

The antibody solution to be tested with and

RECTIFIED SHEET (RULE 91)

ISA/EP

- 53 -

without the free peptide Exon 6 (1-45)NH₂, c = 5 µg/ml was added and incubated for one hour. After a further wash step [0.9% NaCl, 0.05% Tween], 100 µl of a POD-labelled Fab fragment from sheep-sourced polyclonal antibody to mouse-kappa and mouse lambda [BM, mouse Ig determination kit, bottle 2 and bottle 6] was added. It was incubated for 1 h at room temperature. After a further wash step the color substrate, 100 µl, [ABTS, BM: #811769, #687359] was incubated for 30 min at room temperature. The absorbance at 450/490 nm was measured on a Dynatech MR 700 microplate reader.

All positive antibodies including the deposited cell lines were afterwards screened by dot-blot and immunohistology.

Antibodies to recombinant CD44 (fusion protein)

To determine antibody specificity from fusions with recombinant CD44 as antigen, additional screening tests were employed. Antibody samples were tested for reactivity with the fusion protein and for cross-reaction with HIV-gp32 in a parallel ELISA assay. The streptavidin-coated microtiter plates (see section 1) were incubated with biotinylated fusion protein HIV2(gp32)-CD44 exon 6-Bi(XOSU) or HIV2(gp32)-Bi(XOSU) [c = 5 µg/ml, 100 µl/well, 1 h room temperature]. The free binding sites were blocked with blocking buffer [0.9% NaCl, 1% Crotein C, 200 µl, 30 min room temperature]. After a wash step [0.9% NaCl, 0.05% Tween] the antibody sample c = 5-10 µg/ml, diluted in incubation buffer (40 mM sodium phosphate buffer), 100 µl per well and was incubated for 1 h at room temperature. The following steps were done as in the above examples for the synthetic peptide.

Some primary cultures with strong reactivity to the recombinant CD44 and low cross-reactivity

- 54 -

towards HIV2(gp32) protein were obtained. These cultures were further assessed by dot-blot and immunohistology.

5 Determination of specificity of antibodies to cells and tissue (immunostaining)

Method A: Cells from tumor cell lines (e.g. ZR-75 1 or MDA 4A4) were detached from the flask by scraping and the cell suspensions were dropped onto
10 glass slides, dried and fixed with methanol.

Method B: Freeze-dried sections of tumor and normal tissue were fixed with acetone.

After blocking with 5% skimmed milk-TBS at
15 37°C for 60 min, followed by washing with TBS for 2 min, the sample (undiluted cell-culture supernatant) was incubated with antibody for 120 min at 37°C. After carefully washing with TBS X3, further incubation was performed with biotinylated anti-mouse Ig (Dakopatts)
20 for 60 min at 37°C. After further washing (TBS) HRPO avidin-biotin complex (Dakopatts) was added and incubated with the sample at room temperature for 60 min. After washing with TBS X1 1% glutaraldehyde solution was added for 1 min at room temperature.
25 After a further wash step, the substrate (DAB) was added and incubated with the sample (15-20 min). After washing with tap water the nuclei were stained with hematoxylin for 30 sec. The samples were dried and embedded with Cristal Mount (Kaiser's jelly).

30 The results obtained with monoclonal antibody from cell lines MAB<CD44>M-1.1.12 and 4.3.16 are presented in Table 4. In Method B, the MAB 1.1.12 shows high specificity for tumor tissue from the lung, colon and bladder and MAB 4.3.16 revealed specificity
35 for tumor tissue from the colon. In Method A, MAB 1.1.12 and MAB 4.3.16 showed increased reactivity to

- 55 -

the cell line ZR-75-1 (exon 6 high-producer), a human breast cancer cell line (ATCC CRL 1500) than to the cell line MDA4A4 (exon 6 low-producer). This cell line is a subclone of cell line MDA-MB-435S (ductal

5 carcinoma, breast, human; ATCC HTB 129; the subclone was produced according to Bao et al., Differentiation 52 (1993), 239-246; MDA4A4 is identical to MDA-MB-435-C2 of this reference).

10 Within the primary cultures obtained with the recombinantly produced CD44 fusion protein as immunogen (see above) the culture PK 9.00.22 showed a high specificity to tumor tissue of colon with method B. With method A this cultured cell line showed also a marked specificity for the cell line ZR 75-1.

15

20

25

30

35

Table 4: Results of Immunostaining

	Method A cell suspension		Method B tissue		
	ZR75-1 exon 6 high- producer	MDA4A4 exon 6 low- producer	tumor	normal	
MAK 1.1.12	+	-	lung colon bladder	+ + +	- - -
MAK 4.3.16	+	-	colon	+	-

+ strong reaction; - weak reaction

Determination of specificity of produced antibodies by dot-blot

Preparation of cell extracts

Cells of lines HT29 (ATCC HTB 38 - colon adenocarcinoma) and MDA4A4 were cultured in a medium according to ATCC catalogue and were harvested with or without protease additive.

The cells harvested without protease additive were centrifuged, added to double the volume of lysis buffer (50 mM potassium phosphate buffer, 150 mM NaCl, pH 8.0), homogenised for 5 min in a Dounce homogenizer and the quantity of protein determined. On the basis of this protein value, the cellular suspension was adjusted to a protein concentration of 1-2 mg/ml using lysis buffer with or without detergent [1% Triton X-100

- 57 -

(Boehringer Mannheim, Germany Cat. No. 743119), 0.6% CHAPS (Boehringer Mannheim, Germany Cat. No. 810681), 1% HECAMEG (Boehringer Mannheim, Germany Cat. No. 1382225), 0.9% octyl glucoside (Boehringer Mannheim, Germany Cat. No. 411469) or 0.05% dodecylmaltoside (Boehringer Mannheim, Germany Cat. No. 808342)] and stirred for 2 h. After the centrifugation, the supernatant which contains CD44 or CD44v was stored at 4 C or -20 C, and use unchanged. The supernatant obtained after centrifuging off the membranes contained sufficient CD44 (standard form) and CD44v (CD44 with additional exons) for antibody assessment. Because of the mRNA concentration in the cells, it is assumed that MDA4A4 contains predominantly CD44-standard form and hardly any exon 6- containing CD44v. HT29 cells, on the other hand, should contain mainly exon 6- containing CD44v.

A further simple way in which CD44 or CD44v can be obtained is to harvest the cells with trypsin instead of the aforementioned cell harvest with subsequent cellular separation. The supernatant obtained after addition of trypsin inhibitor and centrifuging off the cells also contains sufficient CD44 and CD44v for antibody assessment.

25

Assessment of antibodies by dot blot

Various solutions (synthetical produced CD44 exon6 peptide with the amino acid sequence 1 - 43 as shown in Figure 7 according to example 7, HT29 cellular extract, MDA4A4 cellular extract) were applied to nitrocellulose by capillary tubes. After blocking with Crotein C, incubation of the nitrocellulose with the antibodies (AB) took place. As antibodies the supernatant of the various MAB<CD44>-M cell lines was used. Detection of bound Ab is done with a polyclonal anti Ig antibody conjugated to alcalic phosphatase. For

35

- 58 -

color reaction NBT/X phosphate was used.

The specificity of the reaction can be shown by addition of free Exon6 peptide to the Ab before incubation of the nitrocellulose. If the reaction is
5 specific for Exon6 or CD44v, either no or only very slight binding of the AB to the nitrocellulose takes place after addition of the free peptide. Best results were obtained with the following clones:

- * MAB<CD44>M-1.1.12
- 10 * MAB<CD44>M-2.42.3

The following compounds were spotted onto the nitrocellulose (Schleicher & Schuell 401180) using capillary tubes:

- 15 A: synthetically produced CD44 exon 6, 1-43-NH₂, (0.1 mg/ml)
- B: HT29 extract (1.2 mg/ml)
- C: MDA4A4 extract (1.35 mg/ml)

- 20 After blocking the nitrocellulose with incubation buffer (20 mM Tris/HCl, 150 mM NaCl, 1% Crotein C, pH 7.4), in each case one blot with 2 or 3 dots was incubated using cell culture supernatant (in each case undiluted or diluted 1:4, 1:16, 1:64, 1:256
25 and 1:1024 in incubation buffer). The bound antibody was detected with PAB<M- Ig>S-Fab-AP and 5-bromo-4-chloro-3-indolyl-phosphate/4-nitroblue-tetrazolium chloride (NBT/X phosphate) as color substrate.

- 30 To test the AB specificity the test was run twice in parallel, performing pre-incubation of the antibody in one of the tests using 10 fg/ml of the free Exon6, 1-43 peptide. Inhibition should be seen for an exon 6-specific reaction.

- 35 The antibodies produced by the cell lines MAK<CD44>M-1.1.12 and MAK<CD44>M-2.42.3 are able to bind to dotted CD44 exon 6 peptide and to an extract of

- 59 -

HT29 cells but not to an extract of MDA4A4 cells. Binding of the monoclonal antibody to dotted CD44 exon 6 peptide and to an extract of HT29 cells is specific for the tumorspecific variant of CD44v because preincubation of both antibodies with synthetic CD44 exon 6 inhibits the binding of the antibodies to nitrocellulose (Table 5).

Table 5: Results of dot-blots

Dot-Blot results	Binding to extract of HT 29-cells		Binding to extract of MDA4A4-cells	
	no preincubation of mAb	preincubation of mAb with peptide exon 6	no preincubation of mAb	preincubation of mAb with peptide exon 6
MAK<CD44>M-1.1.12	moderate	low (weak inhibition)	no	no
MAK<CD44>M-2 42 3	strong	no (strong inhibition)	no	no

SUBSTITUTE SHEET

CLAIMS

- 5 1. Antibody specific to the peptide corresponding to CD44 exon 6 having the amino acid sequence shown in Figure 7, its allele variations and phosphorylation and glycosylation products, and characteristic fragments thereof.
- 10 2. Antibody according to claim 1 which is monoclonal or polyclonal.
3. Monoclonal antibody specific to the peptide corresponding to CD44 exon 6 having the amino acid sequence shown in Figure 7 obtainable by the hybridoma
15 cell lines MAK<CD44>M-1.1.12, MAK<CD44>M-2.42.3 or MAK<CD44>M-4.3.16.
4. Monoclonal antibody according to claim 1 which recognize the same epitope as the monoclonal antibodies produced by the hybridoma cell lines
20 MAK<CD44>M-1.1.12, MAK<CD44>M-2.42.3 or MAK<CD44>M-4.3.16.
5. Method for the production of an antibody according to claim 1 comprising injection of a suitable laboratory animal with an effective amount of an
25 antigenic compound comprising the peptide corresponding to CD44 exon 6 having the amino acid sequence shown in Figure 7, its allele variations or characteristic fragments thereof, collecting serum from this animal, and isolation the specific antibody by immuno absorbent
30 techniques.
6. Method for the production of an antibody according to claim 1 comprising injection of a suitable laboratory animal with an effective amount of an antigenic compound comprising the peptide corresponding
35 to CD44 exon 6 having the amino acid sequence shown in Figure 7, its allele variations or characteristic

- 61 -

fragments thereof, isolating the antibody producing cells, immortalization of these cells, screening for the immortal cell line producing the antibody according to claim 1, cloning said immortal cell line and
5 obtaining the antibody from ascites or the supernatant of the cultured immortal cell line.

7. Method for the production of an antibody according to claims 5 or 6 wherein as immunogen the fusion protein of claim 17 or a peptide of claim 13
10 which is coupled to a suitable immunogenic carrier is used.

8. Immunoassay for the detection of a CD44 protein containing the peptide corresponding to CD44 exon 6 wherein an antibody to the peptide CD44 exon 6
15 having the amino acid sequence shown in Figure 7, its allele variations or characteristic fragments thereof is used.

9. Use of an antibody according to any of the claims 1 to 4 for the detection of a CD44 protein.

20 10. Use of an antibody according to any of the claims 1 to 4 for cancer diagnosis.

11. Use of an antibody according to any of the claims 1 to 4 for the detection of antigen-specific immune complexes.

25 12. Standard compound for use in an immunoassay comprising the peptide sequence according to CD44 exon 6 having the amino acid sequence shown in Figure 7, its allele variations, characteristic fragments or secondary modifications thereof.

30 13. Peptide of at least six amino acid length corresponding to an amino acid sequence of CD44 exon 6 shown in Figure 7, its allele variations or characteristic fragments thereof.

14. Peptide according to claim 13 which is
35 coupled to a label, or a solid phase directly or indirectly via two specifically binding partners.

15. Use of the peptides according to claim 13 in an immunoassay.
16. Test kit comprising at least one antibody according to any of the claims 1 to 4.
- 5 17. Fusion protein comprising the peptide corresponding to CD44 exon 6 having the amino acid sequence shown in Figure 7, its allele variations or characteristic fragments thereof.
18. Fusion gene comprising the exon 6 gene shown
10 in Figure 7, its allele variations or characteristic fragments thereof.
19. Use of an antibody specific to the peptide corresponding to CD44 exon 6 having the amino acid sequence shown in Fig. 7, its allele variations and
15 phosphorylation and glycosylation products and characteristic fragments thereof, for the manufacturing of a therapeutic agent for tumour therapy or for an agent for in vivo imaging of tumours.
20. Use of an antibody according to claim 19,
20 which is monoclonal.
21. Use of antibody according to claim 19 or 20, which is a monoclonal antibody to the peptide corresponding to CD44 exon 6 having the amino acid sequence shown in Fig. 7 obtainable by the hybridoma
25 cell lines MAK<CD44>M-1.1.12, MAK<CD44>M-2.42.3 or MAK<CD44>M-4.3.16.
22. Use of an antibody according to claim 19 or 20, which recognizes the same epitope as the monoclonal antibodies produced by the hybridoma cell lines
30 MAK<CD44>M-1.1.12, MAK<CD44>M-2.42.3 or MAK<CD44>M-4.3.16.
23. Use of a monoclonal antibody according to claim 19 to 22 which is a characteristic fragment, a chimeric, humanized or human antibody.
- 35 24. Use of a monoclonal antibody according to claims 19 to 23, which is a human IgG1 antibody.

- 63 -

25. Monoclonal antibody according to claims 1 to 4, which is a fragment, a chimeric, humanized or human antibody.

26. Monoclonal antibody according to claims 1 to 4 or 25, which is a human IgG1 antibody.

10

15

20

25

30

35